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Summary 
  
The γ-herpesvirus Epstein Barr virus (EBV) has evolved during millions of years and has 
adapted very well to its human host. More than 95% of adults worldwide are infected with 
EBV and carry it lifelong in the B cell pool.  
EBV can transform B cells in vitro and was shown to be associated with several human 
cancers like B cell lymphomas and nasopharyngeal carcinoma. 
EBV entry into B cells requires the binding of viral glycoprotein gp350/220 to the cell surface 
receptor CD21 followed by the interaction of the viral tripeptide complex gHgLgp42 with 
HLA class II to initiate the fusion of the viral envelope with the host cell membrane. EBV 
entry into B cells is known to occur without the expression of CD21, but little is known about 
the contribution of other cellular receptors for viral attachment. Nevertheless, integrins are 
considered to be likely involved in CD21independent EBV entry into B cells. Integrins belong 
to a large family of transmembrane cell surface receptors that mediate adhesion between cells 
and their extracellular environment. We previously showed that expression of β1 integrin 
increases the susceptibility of memory B cells, originating from tonsils, to EBV infection. 
However, other integrins might be involved as well, since a whole set of integrins are 
expressed on B cells.  
In the present work we show that integrins indeed play a role in EBV entry into B cells. We 
characterized Burkitt lymphoma (BL) cell lines and primary B cells from tonsils (TBCs) for 
their integrin expression and found that the BL cell line Raji expresses α4β1 integrin more 
abundantly than TBCs and that Raji cells are more susceptible to EBV infection than TBCs. 
Overexpression of the subunit α4 integrin facilitated EBV entry into the BL cell line Akata31. 
Our data indicate that α4β1 integrin plays a role in the process of B cell infection by EBV and 
contributes to enhanced susceptibility of B cell subsets. Furthermore, to investigate the 
function of α4 integrin in depth, we established the best technique for gene knockdown in the 
BL cell line Raji cells. However, silencing with specific siRNA against α4 integrin was not 
efficient. 
It will be important to verify these findings on primary B cells. For this reason we established 
the conditions for efficient separation of naïve and memory B cells from tonsils by magnetic-
activated cell sorting (MACS).  
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Zusammenfassung  
Der γ-Herpesvirus Epstein-Barr- Virus (EBV) hat sich während Millionen von Jahren 
entwickelt und hat sich sehr gut an seinen menschlichen Wirt angepasst. Mehr als 95 % der 
Erwachsenen weltweit sind mit EBV infiziert und tragen es lebenslang in ihren B-Zellen.  
EBV kann B-Zellen in vitro transformieren und es wurde gezeigt, dass EBV mit mehreren 
menschlichen Krebsarten wie beispielsweise B-Zell-Lymphomen und Nasen-Rachen-
Karzinoma assoziiert ist. Der Eintritt von EBV in die B-Zellen erfordert die Bindung des 
viralen Glykoproteins gp350/220 an den auf der Zelloberfläche befindlichen CD21-Rezeptor, 
gefolgt von der Interaktion des viralen Tripeptid gHgLgp42 Komplexes mit  HLA-Klasse II-
Oberflächenmolekülen, um eine Fusion der Virushülle mit der Wirtszellmembran zu 
initiieren. Es ist bekannt, dass der Eintritt von EBV in B-Zellen ohne die Expression von 
CD21 geschehen kann, aber über die Rolle anderer zellulären Rezeptoren für die virale 
Anhaftung ist wenig bekannt, dennoch ist es wahrscheinlich, dass Integrine beteiligt sind. 
Integrine gehören zu einer grossen Familie von Transmembranrezeptoren, welche die 
Adhäsion zwischen Zellen und ihrer extrazellulären Umgebung vermitteln. 
Wir haben bereits gezeigt, dass die Expression von Integrin β1 die Anfälligkeit von 
Gedächtnis-B-Zellen aus Tonsillen gegenüber einer EBV-Infektion erhöht. Andere Integrine 
könnten auch beteiligt sein, da eine ganze Reihe von Integrinen auf B-Zellen exprimiert 
werden.  
In der vorliegenden Arbeit zeigen wir, dass Integrine tatsächlich eine Rolle bei dem EBV 
Eintritt in B-Zellen spielen. Wir charakterisierten Burkitt-Lymphom (BL) Zelllinien und 
primäre B-Zellen aus Tonsillen (TBCs) bezüglich der Expression von Integrinen und haben 
gefunden, dass die BL-Zelllinie Raji α4β1 Integrin höher exprimiert als TBCs und  Raji-
Zellen sind für EBV-Infektion anfälliger als TBCs. Die Überexpression der Untereinheit α4-
Integrin erleichtert EBV den Eintritt in die BL -Zelllinie Akata31. Unsere Daten zeigen, dass 
α4β1 Integrin eine Rolle im Prozess der B-Zellinfektion durch EBV spielt und zu einer 
erhöhten Empfindlichkeit von B-Zell-Untergruppen beitragen kann. Um die Funktion der α4- 
Integrine zu analysieren, haben wir das Gen-Silencing von α4-Integrin in den BL-Zelllinie 
Raji optimiert, jedoch konnte kein effizienter Knockdown erreicht werden. Es wird wichtig 
sein, die gesamten neuen Erkenntnisse in primären B-Zellen zu überprüfen. 
Daher schufen wir die Voraussetzungen für eine effiziente Trennung von naiven und 
Gedächtnis-B- Zellen aus Tonsillen durch magnetische Zellsortierung (MACS)
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Introduction 
 
Epstein-Barr virus (EBV) 
 
Epstein-Barr virus (EBV) is a member of the human γ-herpesvirus family. EBV has 
coevolved with human beings during million of years and, consequently, the virus has 
become well adapted to its human host. More than 95% of the human population is infected 
with EBV and carries it lifelong in the B cell pool with very little threat to the healthy host. A 
primary infection in early childhood is generally asymptomatic and is transmitted via saliva 
among family members (51). An infection occurring during late childhood or adolescence 
may manifest symptomatically and is termed infectious mononucleosis (IM) (51, 157) 
Additionally, IM has been associated with an elevated risk of Hodgkin lymphoma (HL), 
implicating a role for Epstein-Barr virus (EBV) in HL development (65). During the latent 
viral infection phase, virus production or periodic reactivation is continued at a low level to 
avoid immune recognition and, conclusively, EBV may spread through kissing. Therefore, IM 
is also termed kissing disease. 
EBV was not identified because of an acute illness, but was discovered within cells derived 
from a Burkitt’s lymphoma (BL) by Epstein and his colleague Barr in 1964 (44). The virus is 
now estimated to be present in 96% of endemic BL and also in a variety of other tumors (36). 
In B lymphocytes and EBV-associated malignancies different viral transcription patterns are 
observed and have been referred to as latency types 0, I, II and III. 
 
Table 1. EBV latency programs and EBV-associated malignancies. 
Latency program EBNA-1 
LMP-1 
LMP-2A 
LMP-2B 
EBNA-2 
EBNA3s/ 
EBNA-LP 
EBERs 
BARTs 
Associated malignancies 
0    +  
I +   + 
Burkitt’s lymphoma,  
Gastric carcinoma 
II + +  + 
Hodgkin’s lymphoma, 
Nasopharyngeal carcinoma, 
T cell lymphoma 
III + + + + 
Lymphoproliferative disease, 
Infectious mononucleosis 
Adapted from Masucci, 2004 (112). 
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EBV has the ability to transform resting B cells into latently infected lymphoblastoid cell 
lines (LCLs). In EBV transformed LCLs, a small subset of viral gene products, the so-called 
latent proteins, are constitutively expressed: six EBV nuclear antigens (EBNA): EBNA-1, 
EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C and EBNA leader protein (LP); and three latent 
membrane proteins (LMP): LMP1, LMP-2A and LMP-2B. In addition LCLs also show 
expression of the small, non-polyadenylated (non-coding) RNAs EBER-1 and EBER-2 and 
transcripts from the BamHI A region (BARTs) (136). This expression pattern of all latent 
gene products is referred to as latency III and is associated with autonomous B cell 
proliferation. 
Studies with recombinant EBV forms, lacking individual latent genes, confirmed the absolute 
requirement for EBNA-2, LMP-1 in the transformation process and have highlighted a crucial 
role for EBNA-1, EBNA-LP, EBNA-3A and EBNA-3C (189). 
 
Malignancies associated with EBV infections 
Denis Burkitt first described Burkitt’s lymphoma (BL) in 1958 in Uganda (22). He observed 
rapidly enlarging tumors, which were found to be dependent on the climatic and geographical 
conditions of equatorial Africa. This lead to the suggestion that a vector-borne virus might be 
responsible for the development of these tumors (21). In 1964, EBV was first discovered by 
Epstein, Anchong and Barr: They identified herpes virus-like particles in cells cultured from a 
BL biopsy by electron microscopy (44). 
In the late 1960s, it was found that sera from BL patient had higher antibody titers to EBV 
antigens than to sera from healthy control donors (62). Only a few years later, the ability of 
EBV to efficiently transform resting B cells in vitro and to induce tumors in non-human 
primates was confirmed (64, 114, 130). At the same time, it was found that EBV was also 
present in undifferentiated nasopharyngeal-associated carcinoma (NPC) (63, 193). Later 
studies showed an association between EBV infection and a variety of other human tumors 
including B cell malignancies such as Hodgkin’s lymphoma (HL) (179) and 
lymphoproliferative diseases arising in immune-suppressed patients (166), certain types of T 
cell lymphomas, and epithelial tumors such as gastric cancer (33). All these tumors are 
characterized by the presence of multiple extrachromosomal copies of the circular viral 
genome in the tumor cells and expression of the EBV-encoded latent genes, which appear to 
contribute to the malignant phenotype (135). 
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EBV-associated Burkitt’s lymphoma 
Three clinical variants of BL are described according to their geographic distribution: 
endemic, sporadic, and immunodeficiency-associated (68). The endemic BL (eBL) 
characteristically occurs in Africa and affects children at the age of four to seven years, with a 
male to female ratio of 2:1. Affected are the bone of the jaw and other facial bones, as well as 
kidneys, gastrointestinal tract, ovaries, breasts, and other extranodal sites (38). The possibility 
that it encounters an US citizen is 50 times lower (151).  On the other hand, sporadic BL 
(sBL) can occur worldwide: included are those cases, with no specific geographic or climatic 
association. These are 1-2% of the lymphoma in adults and up to 40% of lymphoma in 
children in Western Europe and in the U.S.. The most common site of involvement is the 
abdomen - especially the ileocecal area (the junction between the small bowel and colon). 
Other sites like the ovaries, kidneys, omentum and the Waldeyer’s ring may also be affected 
(48). Immunodeficiency-associated Burkitt’s lymphoma refers mainly to those patients 
infected with the human immunodeficiency virus (HIV) but also to allograft recipients (183) 
and individuals with congenital immunodeficiency.  
Common to all BLs are the chromosomal translocation of the c-myc proto-oncogene and 
it is considered to be the cancer-initiating event in these diseases. The translocations juxtapose 
the c-myc locus (8q24) with the immunoglobulin heavy chain gene  (IGH) on chromosome 
14, or with the kappa light chain gene (IGK) on chromosome 2 or the lambda light chain gene 
(IgL) on chromosome 22 (t(8;14)(q24;q32) or its variants t(2;8) and t(8;22)) (97). Most cases 
of DNA breakpoints in BL are found in rearranged VJ regions or in the S regions of the IgH 
loci. It has been demonstrated that in activated germinal center  (GC) B cells chromosomal 
translocation is mediated by aberrant somatic hypermutation or class switch recombination in 
the presence of the activation-induced cytidine deaminase (AID) (56, 123). Thus, the 
formation of BL cells characteristics has its origin in GCs. As a consequence of the c-myc/Ig 
translocation, transcription of the c-myc locus is under the control of the active Ig locus, 
which results in deregulation and constitutive expression of c-myc RNA and, therefore, 
becomes an oncogene. This translocation, which is a hallmark of BL, drives cells into the cell 
cycle and leads to uncontrolled proliferation and cell growth, but also to apoptosis and 
senescence  
Several pathogens were shown to contribute to BL development – such us EBV, 
Plasmodium falciparum and HIV and will be elucidated in the following paragraph.  
EBV could be associated with BL to varying degrees, but its exact role in the 
development of BL remains elusive and is still an issue of extensive research (44). In the case 
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of eBL it was found that almost 100% of the cells are associated with EBV (3). The 
identification of EBV genomes in all tumor cells (117) indicates that the progenitor tumor cell 
was already infected with EBV. This supports the notion that EBV plays a role at an early 
stage of tumorigenesis. Furthermore, children in Uganda, with higher baseline titers to EBV 
antigens, are at a higher risk of developing eBL (167). The expression pattern of viral genes in 
eBL was found to be restricted to EBNA-1, EBER-1 and EBER-2 and BARTs (16). Since the 
viral antigens required for immortalization are lacking, and neither EBNA-1, nor the EBERs 
and the BARTs display distinct oncogenic properties that might explain EBV’s contribution 
to the pathogenesis of BL, it is still under debate as to how EBV may directly contribute to 
tumor growth (16). EBNA-1, which is expressed in all EBV-positive tumors, was found to be 
required for episomal replication and partitioning of the viral episomes onto daughter cells. In 
the absence of EBNA-1, EBV can also immortalize primary B cells, but in its absence the 
efficiency of B cell immortalization is decreased by at least 10’000-fold (71). Expression of 
EBNA-1 was suggested to be critical for the continued survival of EBV-associated BL by 
inhibiting apoptosis via expression of p53 (91). Studies on transgenic mice expressing EBNA-
1 showed a predisposition to develop B cell tumors (180).  
Evidence that EBERs are implicated in enhanced tumorigenicity and resistance to 
apoptosis comes from transfection studies in the EBV-negative Akata BL cell line. Akata cell 
clones expressing EBER restored the malignant phenotype, resistance to apoptosis and a 
upregulation of bcl-2 protein expression (98). Other Akata transfection studies have also 
shown enhanced survival which was either mediated by virus-induced upregulation of the 
TCL1 oncogene (96) or through induction of IL-10 cytokine expression by EBERs (159). In 
addition, a binding site for MYC has been found in the promoter region of EBER1, and was 
associated to play a specific role of EBV in lymphomagenesis (119).  
Products from BART transcripts (miRNA) were suggested to have a direct impact on 
the cellular gene expression pattern that supports the establishment or maintenance of latent 
infection (17, 149). They have been found in EBV-immortalized latency III cells and BL 
latency I cell lines (12, 20, 26, 150) and in BL biopsies (165, 186). Moreover, studies 
performed recently using BART miRNA mutants indicate that EBV miRNAs contribute to, 
but are not essential for, LCL formation in vitro (45, 46, 144) 
Ironically, although a tremendous progress has been made in the understanding of the 
action of cellular proto-oncogenes like c-myc as well as in the biology of EBV, the molecular 
contribution of EBV to the pathogenesis of BL remains elusive. To investigate the oncogenic 
potential of EBNA-1, EBERs and BARTs, either alone or in cooperation with an activated c-
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myc gene, it may be necessary to develop more robust systems that are not dependent on 
established tumor cell lines, but rather on primary B cells. The reconstruction of the 
pathogenesis of endemic BL in primary human B cells using a mouse model with humanized 
hematopoiesis would be the ultimate goal (16). 
 The malaria parasite Plasmodium falciparum has also shown to be implicated in the 
pathogenesis of eBL. The geographical distribution of the disease suggests undoubtedly an 
immunomodulatory role of the malaria parasite Plasmodium falciparum in eBL. It contributes 
to the increase in number of EBV-positive eBL cases and might also support the 
transformation of these cells. A study from Malawi reported that children expressing high 
levels of antibodies for EBV and carrying, at the same time, the malaria pathogen had a 13 
times higher risk of developing eBL when compared to those children with low antibody 
levels (116). Regardless of their strong association, the relative function of the malaria 
parasite and EBV in the development of BL remains elusive. Additional chronic infections 
induced by malaria leads to polyclonal B cell activation characterized by the occurrence of 
hyperglobulinemia (1). The mechanism leading to this polyclonal B cell activation is still 
unclear. 
 HIV infection is another risk factor for the development of BL. The risk of HIV-
positive patients to develop BL is 200- to 1000-fold higher than of HIV-negative patients 
(14). Immunodeficiency resulting from HIV is responsible for reactivation of EBV in latently 
infected B cells, which might lead to BL (116). As for malaria HIV was shown to induce 
polyclonal B cell activation and hyperglobulinemia (35, 103) 
Hence, the main risk factor for BL development entailed by malaria and HIV seems to be 
polyclonal B cell activation - that may additionally be associated with higher virus titers and 
an increase of EBV-infected memory B cells in vivo. 
 
EBV entry into B cells or epithelial cells 
To enter a cell, the virus has to cross main barriers – such as the cell plasma membrane or 
endosomal membrane. Viruses have evolved various strategies to overcome these barriers. 
The keys to enter target cells are receptors. Some viruses use one specific receptor, whereas 
other viruses interact with at least two plasma membrane components on the cell surface. 
Entry of herpes viruses into the target cell is a very complex process and involves several 
viral ligands and host receptors interactions. Eight EBV glycoproteins are involved in EBV 
entry into B or epithelial cells and different receptor patterns are required depending on the 
cell type (74). 
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EBV preferentially infects B cells and its entry is mediated by binding of viral gp350/220 
(BLLF1) to host cell complement receptor 2 (CR2 or CD21) (49, 52, 164) (Fig. 1). CD21 is 
not only a receptor for EBV entry into B cells, but is also a member of the complement 
system as a receptor for C3d complement fragment (138). 
CD21 is the predominant receptor for EBV attachment to the B cell membrane, but a study 
with mutant EBV lacking gp350/220 showed that this interaction is not absolutely necessary 
for EBV entry into B cells (86). However, binding of gp350/220 to CD21 increased efficiency 
in infection of B cells (86). Monoclonal antibodies against gp350 inhibited B cell infection 
(172). Soluble forms of both gp350/220 and CD21 also inhibited EBV infection and bound at 
the same site as the CD21 antibody (164). These data underline the significance of the initial 
step of gp350/220 binding to CD21. On the other hand, it is most likely that other receptors 
are involved as well. 
 Common for all members of the herpesviruses family is that at least three viral 
glycoproteins (typically gB, gH and gL) are essential for fusion with the host cell (152). For 
fusion of EBV with epithelial cells these viral glycoproteins are sufficient, whereas B cell 
fusion requires additionally glycoprotein 42 (gp42) (Fig. 1). 
Viral gp42 engaged with gHgL and gB interacts with HLA class II (107) which triggers 
fusion of the viral envelope with the B cell membrane (58). But from the HLA alleles, HLA-
DR and HLA-DP and only some HLA-DQ alleles can bind gp42, inducing membrane fusion 
(95). In gp42 fusion studies it has been further demonstrated that an antibody against gH 
interacted with gp42 and prevented the subsequent interaction with HLA class II (107). 
Consequently, EBV-B cell fusion was inhibited (115). Additionally, an antibody against 
HLA-class II prevented interaction with gp42 and blocked infection (107).  
 
Further studies indicated that the complex formed with soluble gHgLgp42 induced membrane 
fusion in the same way as gp42 alone. Interestingly, it was suggested that the cleaved and 
secreted form of gp42 is necessary for B cell membrane fusion (151). The soluble gHgLgp42 
complex did not prevent fusion with epithelial cells. This is in contrast to gp42 only, which 
inhibited epithelial cell fusion. This indicates that gH, gL and gB are sufficient for efficient 
membrane fusion in epithelial cells. gp42 may have an inhibitory effect on the epithelial 
fusion process. Binding of gHgL induces a conformational change that prevents gHgL to bind 
to the receptor. This may be the cause of the inhibitory effect. Similarly, binding of gp42 may 
hinder gHgL to bind to its receptor (95). 
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Figure 1. EBV entry into B cells. 
EBV entry into B cells is initiated by binding of viral gp350/220 to cellular CD21 (1). 
The following interaction of the viral complex gp42/gHgLgB with HLA-class II triggers fusion of 
viral envelope and B cell membrane (2). 
 
 
Contribution of other glycoproteins 
Interestingly, the complex gHgL has been shown to be a specific ligand for αVβ5, αVβ6 and 
αVβ8 integrins on epithelial cells (27). Binding of gHgL to the integrin triggered fusion of 
EBV with the epithelial cell membrane (28). To date, several cell membrane glycoproteins 
have been demonstrated to serve as co-receptors for EBV attachment to or fusion with B cells 
and epithelial cells (28, 43, 171). These glycoproteins have turned out to be integrins. β1 
integrin was shown to interact with viral BMRF2 and is known to induce fusion of EBV and 
epithelial cells (171). 
Our laboratory demonstrated that β1 integrin expressed on memory B cells from tonsils 
interacts with BMRF2. This interaction has a direct influence on downstream signaling 
pathways and, hence, also on the subsequent process of entry (43). 
 
B cell development 
B cells derive from hematopoietic stem cells present in the BM (66). B cell development 
includes several stages of differentiation in the BM before they leave for the peripheral 
compartments (60).  
In the BM B cells pass through several distinct stages of development from the pro-B cell to 
pre-B cell and immature B cell (Fig. 2). During this process, rearrangement of 
immunoglobulin (Ig) genes results in surface expression of the pre-B cell receptor (pre-BCR) 
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and finally of the mature BCR. The first molecular event that leads to the mature BCRs takes 
place in the pro-B cell by random V(D)J gene recombination of the heavy chain. Similar 
rearrangement occurs with the light chain at the pre-B cell stage that includes the V and J 
gene. A productive rearrangement of both, the heavy and light chain, is required for positive 
selection of pre-B cell and progression into an immature B cell stage. To verify a functional 
pre-BCR capable of signal transduction, the pre-BCR is tested with a stromal cell-derived 
ligand, galactin-1. Pre-BCR signalling failure prevents further steps in the B cell development 
and the cell dies (checkpoint 1). 
 
 
 
Figure 2. B cell development. 
B cell development goes trough several distinct stages. In adults, B cell development starts in the BM 
where the rearrangement of the heavy chain of the pro-B cells and the light chain of the pre- B cells 
results in a functional BCR and an immature stage of the B cell. After selection (checkpoint 1 and 2) 
the immature B cells (naïve B cells) migrate to the spleen. Two B cell subsets of mature B cells exist: 
pre-plasma/plasma cells and memory B cells. 
Adapted from Okkenhaug et al. (124). 
 
 
The expression of a functional surface BCR (sIgM) leads to the progression into immature-B 
cells. At this stage, B cells undergo a selection process to prevent development of self-
reactive cells. The autoreactivity is tested against BM-derived antigens (checkpoint 2) (143). 
Cells successfully completing the selection process leave the BM as fully mature naïve B cells 
(158). These naïve B cells eventually mature into follicular B cells or marginal-zone B cells. 
After encountering an antigen, B cells develop through affinity maturation and class 
switching into either antibody-secreting plasma cells or memory B cells.  
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Complement receptors CR1 (CD35) and CR2 (CD21) 
Complement receptors (CR) play an important role in the interaction of the innate and 
adaptive immune system. The expression of CR2 (CD21) is restricted to lymphocytes and 
follicular dendritic cells (FDCs). CD21 has at least four ligands. On the one hand, CD21 binds 
to the cleavage products of C3, namely iC3b, C3dg and C3d. (81).  Additionally, CD21 
interacts with EBV via the surface protein gp350(49), and binds the immunomodulatory 
protein CD23 (7) and cytokine interferon-α (IFN-α) (6).  
CD35 is expressed on multiple cell types such as red blood cells (RBC), myeloid cells and 
lymphocytes. (138). The murine CD21 and CD35 are encoded on the same Cr2 locus and, 
thus, their mRNAs derive from the same gene by alternative splicing (100). In human and 
primates the CR2 gene lost the ability to encode for CD35 during evolution. Apart from this, 
in humans, the exons encoding for the CR1-like domain still exist, but after translation the 
product is not functional. (85). 
On primary B cells CD35 and CD21 form a complex with each other, and CD21 with CD19 
and CD81. CD35 and CD19 complex does not exist (173). 
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Integrins 
Integrins are a large family of transmembrane cell surface receptors. They consist of an α and 
β subunit that form heterodimers (147). These heterodimers belong to the type I 
transmembrane glycoproteins with a short cytoplasmic tail. To date 18 α and 8 β subunits are 
known in mammals and they can assemble into 24 distinct αβ receptors (108, 147, 161). They 
have been discovered about 26 years ago (78) and are among the best characterized adhesion 
receptors due to their multi-faceted functions and features.  
Integrins serve as adhesion receptors and are important for contact to the extracellular 
environment as well as for cell-to-cell communication (161). Cell adhesion is crucial for 
numerous processes such as embryonic development, tissue repair, homeostasis, 
inflammation, cell mobilization and metastasis in multicellular organisms (79). Therefore 
integrin interaction with their ligands is important for attachment, cytoskeletal organization, 
migration, proliferation and survival. Integrins are also involved in pathological processes 
such as inflammation, wound healing, angiogenesis and tumor metastasis. Additionally, 
different microorganisms, such as viruses, can bind to integrins to get access into host cells 
(160).  
Integrins are bi-directional signaling receptors. They can transduce the signal as classical 
receptors from outside-in, but also from inside-out. The outside-in signaling functions by 
binding to extracellular components outside the cell and transfering the signal to intracellular 
adapter proteins or cytoskeletal components inside the cell. The inside-out signaling across 
the plasma membrane mainly acts to bring the integrin into the active conformation. Both 
signaling pathways are accompanied by conformational changes of the integrin structure. The 
usual conformation of integrins on leukocytes in circulating blood is an inactive form, in 
which they cannot bind any ligand or transfer any signal (76). Conformational changes upon 
integrin activation lead to an increased ligand binding affinity and to an interaction with the 
actin cytoskeleton. Thus, integrins link the outside and the inside of the cells. Thereby, they 
transfer a signal from the extra cellular matrix (ECM) to the cytoplasmic tail and its adapter 
proteins to the actin cytoskeleton and activate intracellular signaling pathways or vice versa 
(19, 78). 
 
Integrin structure 
Integrins are non-covalently linked α / β heterodimers and they are named after their ability to 
integrate both the ECM and the actin cytoskeleton by signaling bidirectional. (77, 163). They 
are type I transmembrane glycoproteins with a large extracellular domain, a short single 
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membrane spanning helix and a short cytoplasmic domain (Fig. 3A) (23). They are composed 
of a globular extracellular head, which consists of both subunits, which are connected by two 
long stalks or legs to the membrane (118, 154). The α and β subunits do not share 
homologous sequences. But some α and β subunits show sequence similarities among their 
respective subunits (10). 
All integrin heterodimers have several divalent cation binding sites which are important for 
ligand binding (169). Different divalent cations have distinct effects on ligand affinity. Mn2+ 
and Mg2+ support ligand binding, but latter to a lower extend. On the other hand Ca2+ does 
inhibit ligand binding (54). The divalent cation binding site and the region involved in ligand 
recognition are in close proximity (34, 184). 
 The α subunit consists of a seven-bladed β propeller, which is linked to a thigh, a calf-1, 
and a calf-2 domain (10, 154). The β propeller contains a domain that binds three to four Ca2+ 
cations. These Ca2+ binding sites have an important impact on the ligand binding activity (126, 
191).  An additional Ca2+ site is located on the Genu. Studies showed that the Ca2+ always 
occupies this site- in both bent and extended conformation. However, the precise function of 
this Ca2+ binding is still unknown (191). The half of the α subunit contains an additional αI 
domain (Fig. 3B). The αI domain is present in the β2 integrin subgroup of integrins, in the 
collagen-binding integrins belonging to the β1 subfamily (α1, α2, α10, and α11), and the αE 
integrin chain forming the αEβ7 heterodimer. Ligand binding induces conformational changes 
in the αI domain, which also alters the conformation of the β subunit ultimately affecting 
ligand-binding affinity (108, 155). The αI domain contains a metal ion-dependent adhesion 
site (MIDAS) motif. This motif harbors a Mg2+ ion which is coordinating ligand binding 
(105). Integrins that possess an αI domain can bind ligands through this domain.  
The α subunit has the greatest influence on ligand binding specificity (108). In α subunits 
without an αI domain (Fig. 3C), the ligand-binding site is located at the interface between the 
α subunit β propeller and the β subunit βI domain. The specificity for ligand binding is 
determined by the α subunit although the βI domain is involved in ligand binding in αI-less 
integrins (155).  
 The β subunit consists of a plexin-semaphorin-integrin (PSI) domain, a hybrid domain a 
βI domain and four cysteine-rich epidermal growth factor (EGF) repeats (10). In contrast to 
the αI, the βI domain possesses three metal ion-binding sites. At the center resides one 
MIDAS, which binds Mg2+ and is flanked by two additional ion-binding sites. These binding 
sites are called synergistic metal ion-binding site (SyMBS) and adjacent to MIDAS 
(ADMIDAS) and both of them bind Ca2+ (191).  
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Figure 3. Schematic illustration of the integrin subunits and their potential conformations. 
A) Primary structure of integrin α and β subunit. The αI domain is indicated with dashed lines. 
Asterisks mark the Ca2+ binding site in the β propeller. (B and C) Conformational changes of the αI 
containing domain (B) and a αI-less integrin (C) during integrin activation.  
Model from Zhang et al. 2012 (191). 
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Inside-out and outside-in signaling 
Depending on the extracellular or intracellular binding of ligands, the resulting 
conformational change and signal transmission is termed inside-out or outside-in signaling. 
The induced conformational changes or integrin activation include rearrangement of 
extracellular, transmembrane and cytoplasmic domains. 
On the cell surface integrins exist usually in an inactive or non-adhesive state that is 
characterized by a bent or folded conformation. This is characterized by a folded 
conformation of the extracellular domain, a closed head and a low affinity for ligands (70, 
108). To bind ligands, integrins must be in an activated state. Extracellular ligands, which are 
bound to B cell receptors (BCRs) or chemokine receptors, can trigger an intracellular signal to 
activate integrins. In this context, chemokine triggering was shown to induce a 
conformational change of integrins leading to an enhanced integrin affinity and was 
recognized as a mechanism controlling integrin-mediated adhesion (32).  
Binding of an intracellular ligand, such as talin, to the cytoplasmic tail of the β subunit 
transforms the bent conformational state to an extended and more active form exposing the 
ligand-binding site. The extended form exists in two different conformations: either with a 
closed headpiece and with a low ligand affinity, or with an open headpiece and a high affinity 
for ligands. The swing out of the hybrid domain and the dissociation of the cytoplasmic 
domains results in an open conformation and in a higher affinity of integrins for ligands (108, 
155, 162). 
Inside-out signaling is characterized by binding of an intracellular ligand, such as talin or 
kindlin, to the integrin cytoplasmic tail. This ligand binding induces a conformational change 
of the extracellular domain thereby increasing the integrin affinity and clustering of the 
integrins in the membrane. As a consequence, the cell can regulate adhesion and migration 
(2). Adhesiveness can be quickly modulated by inside-out signaling (154). 
Like classical receptors, integrins can also transfer signals from outside-in. Extracellular 
changes, such as ion concentration, can trigger a conformational change from a bent to an 
extended state and can activate many intracellular signaling pathways (106). Although both 
processes of inside-out and outside-in signaling are described separately, they are often 
closely linked. Integrins can be activated by intracellular signaling and, in parallel, increase 
ligand binding, which results in outside-in signaling. Alternatively, ligand binding can induce 
an intracellular signaling that causes a subsequent inside-out signaling and increases, for 
example, ligand binding.   
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Integrin ligands 
Every cell type expresses a certain pattern of integrins and, depending on the combination of 
α and β subunits, cells can bind different ligands. Additionally, it is very characteristic for 
integrins to have the ability to bind multiple ligands. Moreover, many ECM ligands and cell 
surface proteins bind to multiple integrin receptors (73, 129). Based on their ligand-binding 
specificities integrins can be clustered into four subgroups. Most integrins recognize a very 
short motif on the ligand. The first group of integrins binds to the tripeptide sequences 
arginine-glycine-aspartic acid (RGD) (76). This group includes αIIβ3, all αv, α5β1 and α8β1 
(Fig. 4, turquois). The amino acid sequence RGD is embedded in several molecules such as 
fibronectin, vitronectin, fibrinogen, the transforming growth factor-β (TGF-β) and several 
other ECM proteins (72). Another motif, to which integrins bind to, is the minimal key 
sequence LDV (leucin-aspartic acid-valine) or structurally related sequences (30, 170, 176). 
LDV is functionally related to RGD and both motifs are bound at the junction between the α 
and β dimer (72). The LDV motif is found in the alternatively spliced domain of fibronectin, 
the connectin sequence 1 (CS1) and in ligands such as vascular-cell adhesion molecule-1 
(VCAM-1) and mucosal addressin cell adhesion molecule-1 (MadCAM-1). Integrins, such as 
α4β1, α4β7, α9β1 and the four members of the β2 family, interact with these ligands (Fig. 4, 
yellow) (72). 
 
Figure 4.  Representation of the integrin family. 
The color code of the circles indicates the binding specificity of the heterodimer: RGD-binding 
integrin: turquois, LDV-binding integrin: yellow, GFOGER-binding (collagen) integrin: purple, 
laminin-binding integrin: green. Integrins selectively expressed in B cells have gray-striped α-subunits 
and are connected with red lines to the corresponding β-subunit. 
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A third group of integrins binds to the GFOGER motif. This is a sequence found in molecules 
such as collagen. This group comprises the integrins α1, α2, α10 and α11 (purple). The fourth 
group of integrins binds laminins. The binding integrins are formed by three β1 integrins (α3, 
α6 and α7) and α6β4 (green) (72). 
 
Integrin expression on B cells 
Since integrins are important for many cell processes they have also been investigated in B 
cells. Integrin αMβ2 was shown to be involved in B cell adhesion to the basolateral 
membrane of epithelial cells during transfer infection of EBV (Figure 4) gray-striped α-
subunits indicate integrins expressed selectively in B cells (145). Another study demonstrated 
that αM integrin is associated with the BCR forming a receptor complex on the B cell surface. 
This receptor complex negatively regulates BCR signaling to maintain autoreactive B cell 
tolerance (39). The α5β1 integrin was shown to facilitate EBV attachment to memory B cells 
from tonsils (43). Integrin α6β1 and αVβ1 were found to be important during B cell activation 
on tonsillar B cells (122). In addition αLβ2, α4β1 and α4β7 are crucial for migration and 
development of B cells (192). 
 
The α4 integrin subunit family 
α4 integrins are expressed on several cell types including hematopoietic stem progenitor cells 
(HSPCs), T and B cells, natural killer (NK) cells, monocytes, eosinophils and basophils (5, 
87, 133, 175). α4 integrin plays a role in leucocyte recruitment to sites of inflammation. Thus, 
it is also expressed on neutrophils- even though only at a low level (15). α4 integrin can 
dimerize with two β subunits, namely β1 and β7 (187). The heterodimers α4β1 and α4β7 bind 
to LDV, which is a key recognition sequence for ligand binding. Both heterodimers bind to an 
alternatively spliced segment of CS1 that is a domain fibronectin (FN) and to osteopontin. 
The vascular cell adhesion molecule (VCAM-1) is the principal ligand for α4β1. It contributes 
to lymphocyte homing to bronchial-associated lymphoid tissue (BALT) and is important in 
tissue migration during inflammation (80, 185). α4β1 can, to a minor extend, also bind to the 
mucosal vascular addressin cell adhesion molecule (MadCam-1). α4β7 also binds to VCAM-
1, but MadCam-1 is the main ligand, which acts as a homing receptor to the intestinal Peyer’s 
patch high endothelial venules (HEV’s) (109, 187). Tethering and rolling on the endothelium 
can be induced by α4 and depends on rapid activation by chemokines (139). α4 integrins play 
a crucial role in leucocyte development and are of special importance in B and T lymphocyte 
development. In this regard, α4 integrins retain the hematopoietic progenitors in the bone 
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marrow (BM) stroma to ensure a normal early development (18). Moreover α4 inhibits 
apoptosis in germinal center B cells (99). In addition, crosslinking of α4 integrin prevented B 
cells from apoptosis and upregulated the antiapoptotic B cell lymphoma gene Bcl-XL (61). 
Hence, α4 integrin is essential for several biological activities and the basis of these activities 
can be found at the cytoplasmic tail. The cytoplasmic domain of α4 integrin is the only α 
subunit, which binds tightly to the signalling adapter protein paxillin. The binding of paxillin 
to α4 cytoplasmic domain leads to recruitment of other intracellular signalling and adapter 
molecules and induces the biological properties of α4 integrin (139). α4β1 integrin was also 
shown to engage with the tetraspan protein CD81. This engagement with CD81 modulates its 
function, a process termed cross talk (131). 
Thus, CD81 may associate with α4β1 integrin and participate in functionally relevant 
interactions. 
 
Integrins are involved in the entry of herpesvirus into the cells  
Herpesviruses interact with various components on the cell surface and follow different entry 
routes. For instance, they have been described to enter cells by interacting with different 
integrins (Table 2). Binding of EBV to epithelial cells is suggested to occur via the viral 
envelope protein gH and/or the EBV-specific BMRF2 glycoprotein, which has an RGD 
integrin-binding motif (152, 153). gH is thought to bind to αVβ6 and αVβ8 integrins via a 
KGD motif (75) and the BMRF2-RGD domain was suggested to interact with α3, α5, αV and 
β1 (182). After the initial attachment of EBV to the epithelial cell surface via BMRF2 or 
gH/gL, a conformational change in gHgL allows, most likely, the fusion of virus and cell 
surface. 
In B cells, so far, only α5β1 was shown to play a role in EBV infection (43). It was suggested 
that α5β1 was used to attach to memory B cells from tonsils, tethering EBV closer to the cell 
surface, and, thus, facilitating EBV infection of B cells.  
 Kaposi’s sarcoma-associated herpesvirus (KSHV) enters target cells by utilizing a 
variety of receptors. The KSHV entry is mediated by interaction of viral gB with cell surface 
heparan sulfate and integrins α3β1, αVβ3 and αVβ5 (24, 92). α3 integrin was identified to 
play a crucial role in virus-induced cell fusion (174).  
To enter a host cell, human cytomegalovirus (HCMV) simultaneously and 
independently coordinates binding to epidermal growth factor receptor (EGFR) (through gB) 
and the coreceptor αVβ3 (trough gH). The binding induces both EGFR-dependent PI3K and a 
αVβ3-dependent Scr signaling (177). β1 integrin was also suggested to be involved in 
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facilitating HCMV infection. But it needs to be investigated, whether β1 uses the same 
mechanisms as αVβ3 to enhance infection. 
 Herpes simplex virus 1 (HSV-1) enters cells in a receptor-dependent fashion (nectin1 or 
herpesviruses entry mediator (HVEM)) by the use of different mechanisms such as 
endocytosis, macropinocytosis/phagocytosis (55) or membrane fusion (127). A recent study 
considered two hypotheses: Firstly, αVβ3-integrin may bind HSV-1 and trigger endocytosis 
of the virus. Alternatively, αVβ3-integrin does not interact with HSV-1, but may modify, or 
even suppress, a common pathway of HSV-1 entry into target cell. Hence, αVβ3 integrin 
would become a functional sensor against HSV infection (55). 
Equine herpes virus 1 (EHV-1) is a member of the Alphaherpesvirinae subfamily (9, 
125), and enters equine epithelial cells via direct fusion at the plasma membrane (8).  
 
Table 2. Integrins as entry receptors for herpesviruses. 
 
 
Gene analysis by loss- and gain-of-function studies 
A lot of knowledge about mammalian cell regulation has been achieved with the aid of loss- 
and gain-of-gene function studies. For this purpose, exogenous genetic material, DNA and 
RNA can be introduced transiently or stably by transfection.  
A very powerful tool has emerged from the discovery of the cellular process of RNA 
silencing (RNAi). RNAi is a post-translational process triggered by introduction of double-
stranded (ds) RNA, which initiates the degradation of homologous RNA resulting in reduced 
protein expression (50). Long endogenous dsRNAs initiates RNAi by activating the RNase III 
family member termed Dicer (13). The Dicer binds and cleaves dsRNA into short 21 to 23 
long nucleotide fragments, called small interfering (si) RNAs. The siRNA is taken up by the 
RNA-induced gene silencing complex (RISC) with the assistance of Argonaute 2 (Ago2). In 
Sub-family Genus Integrin Cell entry Cell type 
γ-herpesvirinae HHV-4; EBV β1 (43), αVβ1, α3β1, 
αVβ1 (182), αVβ6, αVβ8 
(75) 
Attachment, fusion B cells, epithelial cells 
γ-herpesvirinae HHV-8, (KSHV); 
Kaposi’s sarcoma-
associated 
herpesvirus 
α3β1, αVβ3, αVβ5 (24, 
92, 174) 
Fusion Endothelial, B, fibroblasts, 
epithelial cells, DCs, monocytes 
β-herpesvirinae HCMV; Human 
Cytomegalovirus 
α2β1, α6β1, αVβ3 (47, 
177) 
 
Post-attachment Fibroblasts 
α-herpesvirinae HSV-1: Herpes 
simplex virus -1 
αVβ3, αVβ8 (55, 127) Endocytosis Epithelial cells, cells of the cenral 
nervous system 
α-herpesvirinae EHV-1: Equine 
herpesvirus-1 
α4β1 (8) Fusion Equine epithelial cells 
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the RISC, the passenger strand of the siRNA duplex is degraded while the other strand, the 
guide strand, directs the activated RISC to the complementary sequence in the target mRNA. 
The Ago2 component of the RISC is a ribonuclease which cleaves the target mRNA resulting 
in silencing of the corresponding gene and shutting down of protein synthesis (42). Two 
approaches have evolved to take advantage of the RNAi machinery to shut down gene 
expression: (i) use of siRNA or (ii) expression of small-hairpin RNA (shRNA) that are 
cleaved to active siRNA. The stable transfection of shRNA can be used for effective long-
term silencing. In some cases it can cause cytotoxicity due to competing cellular factors, 
resulting in limitation of the latter (4, 57). On the other hand, chemically synthesized siRNA 
may silence host gene expression also very efficiently without misbalancing host cellular 
factors. Although preclinical experiments have shown their effectiveness, the features of 
siRNAs’ pose a challenge in delivery and uptake into cells. The plasma membrane is a 
significant barrier for siRNA uptake. The negative charge and the hydrophilicity of siRNA 
molecules prevent them from crossing biological membranes (42).  
Unfortunately, no single transfection method can be applied for all types of cells. Facilitation 
of siRNA uptake is achieved with various approaches, because cellular cytotoxicity and 
transfection efficiencies vary dramatically - depending on the reagent, protocol and cell type 
being utilized. 
Therefore, numerous transfection methods, such as liposome transfection, calcium phosphate 
precipitation, electroporation, microinjection and magnetofection are used (Table 3).  
 Recently, a new RNA-based method was described, CRISPR interference (CRISPRi) 
for targeted silencing of transcription in bacteria and humans (104). The CRISPR (clustered 
regularly interspaced palindromic repeats) and CRISPR associated (CAS) system is derived 
from the Streptococcus pyogenes and provides protection from invading viruses and plasmids. 
Bacteria harbouring CRISPR/CAS loci target foreign DNA with a short complementary 
single-strandet RNA (CRISPR RNA or crRNA) that localizes the CAS9 nuclease to the target 
DNA sequence (156). 
While RNAi must target many copies of messenger RNA in order to silence gene expression, 
CRISPR-CAS silences gene expression already at the DNA level. This complex causes a 
double-stranded break at the desired DNA sequence. Several groups have so far demonstrated 
that the CRISPR/CAS9 system is a very efficient tool in various species (25, 29, 31, 53, 69, 
88, 110, 146, 190).  
 
 
Introduction 
 
 
19 
Table 3. Conventional transfection methods. 
Class  Methods Advantages Disadvantages Examples Refs 
Biological • Virus- 
 mediated 
 
 
 
 
 
-High efficiency 
 
 
-Easy to use 
 
-Effective on 
dissociated cells, 
slices, and in vivo 
 
 
-Potential hazard to 
laboratory personnel 
 
 
 
- Insertional 
mutagenesis 
 
-Immunogenicity 
-DNA package size 
limited 
Herpes simplex, 
Adeno virus, 
Adeno-associated 
virus, Vaccinia 
virus, Sindbis virus,  
(59, 
128, 
137, 
168, 
181) 
Chemical • Cationic 
polymer 
 
• Calcium 
phosphate 
 
• Cationic lipid 
 
-No viral vector 
 
-High efficiency 
 
 
-Easy to use 
-Effective on 
dissociated cells and 
slices 
-Plenty of 
commercially 
available products 
-No package size 
limit 
-Chemical toxicity to 
some cell types 
-Variable transfection 
efficiency by cell type 
or condition 
-Hard to target specific 
cells 
 
DEAE-dextran, 
polyethyleneimine 
polybrene, calcium 
phosphate, 
lipofectin, DOTAP, 
lipofectamine, 
CTAB/DOPE, 
DOTMA 
X-tremeGENE 
(67, 
140, 
178) 
Physical • Direct injection 
 
 
• Biolistic 
particle 
delivery 
 
• Electroporation 
 
• Laser-
irradation 
 
 
• Sonoporation 
 
• Magnetic 
nanoparticles 
-Simple principle 
and straightforward 
 
-Physical relocation 
of nucleic acids into 
cell 
 
-No need for vector 
 
-Less dependent on 
cell type and 
condition 
 
-Single-cell 
transfection 
-Needs special 
instruments 
 
-Vulnerable nucleic 
acids 
 
 
 
-Demands experimenter 
skills, 
laborious procedure 
Micro-needle, 
AFM tip, GENE 
Gun, Amaxa 
Nucleofector, 
NEON, 
phototransfection, 
Magnetofection 
(11, 41, 
82, 83, 
93, 111, 
113, 
120, 
141, 
142, 
148, 
188) 
Adapted from Kim et al. 2010 (94). 
 
Transfection methods have developed rapidly, even within one organism. Many new 
products are launched each year with improved efficiency and less cytotoxicity. 
Consequently, we have many options to choose from, fitting well into our experimental or 
clinical needs. Future studies should focus on the in vivo safety of the various delivery 
systems for clinical application, such as the RNAi-based cancer therapeutics. 
 Loss-of-function studies alone are usually insufficient to deduce gene function. 
Additional genetic approaches such as gene overexpression are needed.  
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Foreign genetic material, such as plasmid DNA (pDNA) can be introduced transiently or 
stably. Cells transiently transfected with pDNA receive the pDNA and express it before 
integration into genomic DNA takes place. But with every cell cycle the pDNA gets diluted 
and, consequently, will disappear from the cell population over time. 
This is in contrast to stable transfection of pDNA where a stable cell line is generated. The 
stable transfection is a permanent integration of pDNA into the genome of target cells. The 
introduced foreign DNA is expressed by the cells continuously even after many generations 
of cell divisions. 
Usually, an expression plasmid is integrated randomly into the genome of the target cell. The 
random integration sometimes leads to silencing of the transgene.  This drawback initiated the 
development of several strategies to overcome the negative effects of random integration. 
Strategies such as site-specific, homologous and transposon-mediated integration are used, 
but require the expression of integration enzymes or additional sequences within the plasmid 
(84, 90). 
Overexpression studies have several advantages: (1) they have dominant effects and, thus, can 
be performed readily in diploid organisms; (2) they provide functional links even for 
redundant gene; (3) they identify complementary interactions from loss-of-function screens 
(132).  
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Subject of Investigation 
 
This dissertation investigates the involvement of integrins in EBV infection of B cells. The 
following topics address the primary focus of this thesis: 
 
1) The role of α4 integrin in EBV entry into B cell  
CD21 is the main receptor for EBV entry into B cells. This was tested by the use of a 
soluble CD21 that prevented infection of B cells. Additionally, experiments with a 
gp350-null EBV mutant demonstrated that EBV is still capable of infecting B cells 
and, hence, the existence of an additional cell surface receptor was suggested. 
Integrins could be involved in EBV entry into B cells since α5β1 integrin has already 
been shown to be implicated. We investigated the expression of integrins on B cells 
and tested whether overexpression of α4β1 integrin in a CD21 negative B cell line 
increased susceptibility to EBV infection.  
 
2) Investigating integrins as possible EBV entry receptors by using blocking 
antibodies against integrins or by gene knockdown 
A whole set of integrins is expressed on B cells. We investigated the involvement of 
these integrins in EBV infection of B cells by several methods.  
. 
 
3) Separation of naïve and memory B cells from tonsils by magnetic-activated cell 
sorting (MACS) 
In this dissertation, we characterized integrin expression on B cells and showed a 
novel role of α4 integrin in EBV entry into B cells. The investigations were done in B 
cell lines and future studies will be necessary to study the obtained knowledge in 
primary B cells. Im this context, we focused on TBCs since they are located in the 
tonsils and, hence, are present at the portal of EBV entry. 
Separation of naïve and memory B cells is a crucial pre-requisite for many 
experiments investigating this process. Therefore, we established the separation of 
naïve and memory B cells from tonsils by magnetic-activated cell sorting (MACS). 
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4) Early gene expression changes by EBV infection of B cells suggesting CDKs and 
survivin as therapeutic targets for post-transplant lymphoproliferative diseases 
A variety of EBV viral proteins are expressed in EBV-associated lymphoproliferative 
diseases (LPDs), and these have been shown to influence the potential risk for 
lymphomagenesis. 
Early molecular events, leading to B cell transformation by EBV, were investigated. 
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Results 
 
 
1) The role of α4 integrin in EBV entry into B cells 
 
Patricia Krukowski, Michele Bernasconi and David Nadal  
 
Experimental Infectious Diseases and Cancer Research, University Childrens Hospital of 
Zurich, University of Zurich 
 
 
Manuscript in preparation 
 
The γ-herpesvirus Epstein Barr virus (EBV) was demonstrated to infect B cells in a CD21-
dependent and -independent manner. We have previously shown that α5β1 plays a role in 
EBV infection of B cells however the role of other integrins in this process remains elusive. 
We investigated Burkitt lymphoma (BL) cell lines and primary B cells from tonsils (TBCs) 
for their integrin expression. We show here that the BL cell line Raji expresses α4 integrin 
more abundantly than TBCs and is also more susceptible to EBV infection than the latter. 
Moreover, overexpression of the subunit α4 integrin facilitated EBV entry into the EBV-
negative cell line Akata31, but not in the EBV negative cell line BJAB. Our data indicate that 
α4β1 integrin plays a role in the process of B cell infection by EBV and may contribute to 
enhanced susceptibility of B cell subsets to EBV infection thus promoting survival of the 
virus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work was primarily done by Patricia Krukowski.
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Material and Methods for Chapter 2 + 3 
 
Cell culture and virus. 
All B cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) 
(Invitrogen, Basel, Switzerland), 1% L-glutamine, and 1% penicillin-streptomycin (Gibco, 
Basel, Switzerland) in a humidified 5% CO2 atmosphere at 37°C. 
Primary B cells were obtained from donors undergoing tonsillectomy. Peripheral blood 
mononuclear cells were obtained from healthy donors. The B cell line Raji originates from 
Burkitt Lymphoma biopsies and is EBV positive. 
HEK 293 cells carrying stably expressing wildtype EBV BAC (D2089; EBV-wt B95.8)) 
(kindly provided by Henri Jacques Delecluse (DKFZ, Heidelberg, Germany) have been 
previously described (37). Cells were maintained in DMEM, 10% fetal bovine serum (FBS), 
1% L-glutamine, 1% penicillin-streptomycin and 100 µg/ml Hygromycin (LabForce, 
Nunningen, Switzerland). 
 
Antibodies and reagents. 
Inhibitory antibody anti-CD20 mab-1048, HLA-DR mab-Tu39 (BD Bioscience, Allschwil, 
Switzerland), anti-CD21 mab-AT80 (AbD SeroTec, Düsseldorf Germany), anti-integrin 
αL/CD11a mAb-HI111, anti-integrin β1/CD29 mAb-JB1A, anti-integrin β2/CD18 mAb-
P4H9, anti-integrin α4/CD49d mAb-P4C2, anti-integrin αV/CD51 mAb-LM609, anti-integrin 
α6/CD49f mAb clone NKI-GoH3 (Chemicon, Millipore, Zug, Switzerland), anti-IgG mab 
(AbD Serotec, Düsseldorf Germany). 
Anti-CD19 mAb pacific blue (PB)-LT19 (AbD Serotec, Düsseldorf, Germany, anti-CD27 
mAb phycoerythrin (PE)-L128 (BD Bioscience, Allschwil, Switzerland). 
 
Isolation of primary cells. 
Preparation of tonsillar and peripheral blood mononuclear cells was done as previously 
described (101). 
 
Virus preparation and infection. 
Free virus in supernatant was harvested from induced 293/EBV-wt cells. 293 cells at 80% 
confluency were transfected in 100mm Petri dish with expression plasmids (5 µg each/dish) 
encoding the BZLF1 and the BALF4 gene products, using the liposome-based reagent 
Metafectene (Biontex, Martinsried/Planegg, Germany). After 5 hours, the transfection mixture 
was removed and cells were kept in DMEM supplemented with 10% fetal bovine serum 
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(FBS), 1% L-glutamine, and 1% penicillin-streptomycin. Three days post virus induction, 
virus supernatant was filtered trough a 45 µm pore size filter and stored at 4°C until use. 
Determination of infectious EBV particles was done as described in (40).  
B cells were infected with viral supernatant of multiplicity of infection (MOI)=6. After  
24 hours medium was replaced and cells were analysed by flow cytometry for EBV infection. 
 
Real-time polymerase chain reaction (RT-PCR). 
Total RNA isolation, DNAse treatment, reverse transcription and RT-PCR were performed as 
described earlier (102, 134). 
qPCR was performed for the integrins α3, α4, α5, α6, αE, αL, αM, αV, β1, β2,  β4 and  β7 and 
integrins were normalized to the housekeeping gene hydroxymethylbilane-synthase (HMBS) 
and further normalized to control (depicted as 2ΔΔct). Total RNA was isolated after 24 hours 
post splitting the cells. All subunits and HMBS were analyzed using primer/probe on demand 
(Assay-on-demand gene expression product; Life Technologies, Zug, Switzerland). 
 
Flow cytometry. 
Flow cytometry was performed using a FACS Canto II flow cytometer (Beckman Coulter, 
Nyon Switzerland). Flow cytometry data were analyzed with FlowJo. 
 
Knockdown of α4 integrin or CD21 expression with siRNA. 
Raji B cells were split 24 hours before transfection. On the day of transfection, Raji cells were 
either transfected with negative control or with α4 integrin specific or control siRNA (Qiagen 
Allstars Negative Control siRNA Cat # 1027284) using liposomal method with HiPerFect 
(Qiagen, Basel, Switzerland), XtremeGENE (Roche, Rotkreuz, Switzerland) or NEON 
transfection systems (Life Technologies, Zug, Switzerland).  
HiPerFect: 24 hours prior to transfection, cells were split. 200 000 Raji cells were transfected 
with 750 ng of siRNA in 100 µl culture medium without serum and 6 µl HiPerFect 
Transfection reagent. After 6 hours culture medium with antibiotics was added. 48 hours post 
transfection cells were analyzed by flow cytometry. 
XtremeGENE: 200’000 cells were transfected with different ratios of transfection reagent 
and siRNA (10:2, 2.5:0.5 and 1:0.2). 48 hours after transfection, cells were harvested for 
detection of surface integrin expression by flow cytometry.  
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shRNA introduction with lentiviral particles. 
1x105 cells/mL in 1ml were transferred into sterile 15 ml Falcon tubes.  
MISSION lentiviral particle solution was added to the cells such that the final MOI was 4.0 
per Falcon tube.  
Falcon tubes with cell-virus mix were centrifuged at 800 x g for 60 minutes at 32 °C. 
Subsequently the virus-containing medium was aspirated and disposed. Each cell pellet was 
resuspended in 1 ml of completed RPMI by gently pipetting the pellet up and down, and each 
resuspended pellet was transferred to a well in a 12-well culture plate. The plate was 
incubated for two days in the incubator at 37°C and 5% CO2. After 2 days, media was 
removed and replaced with 2 ml RPMI complete media containing puromycin (Raji: 800 
ng/mL; BJAB: 900 ng/ml.  
Cells were maintained in puromycin until the non-transduced negative control cells have died 
as determined by inspection or Trypan Blue staining. 
Lentiviral transduction particles are specified in the appendix. 
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The following two chapters (2 + 3) include additional unpublished results. 
 
2) Inhibition of EBV entry into B cells by targeting integrins with blocking 
antibodies or gene knockdown 
 
Blocking of CD21 and HLA-DR, but not integrins by specific antibodies, reduced EBV 
infection of B cells 
To determine whether integrins play a role in EBV entry into B cells (74, 153), we performed 
experiments using blocking antibodies hindering EBV binding to integrins on Raji cells and 
TBCs. 
In order to titrate the antibodies used for the blocking experiments, Raji cells were incubated 
with different concentrations of specific antibodies for CD21, and control antibodies specific 
for CD20 and IgG. In a next step, the cells were spinoculated with GFP-tagged EBV-wt and 
analyzed by flow cytometry for the percentage of positive cells and mean fluorescence 
intensity (MFI) (Fig. 5A and B). 
Incubation with an antibody specific for CD21 and with a concentration of 10 µg/ml 
displayed the highest reduction of susceptibility to EBV infection, demonstrating a significant 
reduction of GFP expression (30%). These results are comparable to previous publications 
(43). Control antibodies specific for CD20 or IgG had no effect at the different concentrations 
used. A higher antibody concentration (25 µg/ml) showed a toxic effect on Raji, likely caused 
by sodium azid. 
 
 
 
 
Figure 5. Titration of blocking antibody against CD21 on Raji cells. 
Raji cells were incubated with anti-CD21 or control antibodies anti-IgG1 or anti-CD20 (0.1 µg/ml, 1 
µg/ml and 10 µg/ml) before spinoculation with EBV. Infected cells were identified by flow cytometry. 
(A) Depicted are percentages of GFP positive Raji cells and (B) mean fluorescence intensity (MFI). 
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To test whether integrins are required for EBV entry into B cells, we used blocking antibodies 
directed against α4, αL, αV, β1 and β2 integrin and tested EBV binding to TBCs and Raji 
cells. The blocking antibodies did not exhibit any inhibitory effect on EBV infection neither 
in tonsillar memory (CD191+ CD27+), naïve (CD19+CD27-) B cells (Fig. 6A) nor in Raji cells 
(Fig. 6B). Incubation with control antibody specific for CD21 resulted in a reduction of GFP 
positive TBCs of about 65% and 60% Raji cells. As expected, incubation with control 
antibody directed against CD20 had no effect.  
 
 
 
Figure 6. α-CD21 and α-HLA-DR blocking antibodies inhibited EBV infection but not 
integrin function blocking antibodies. 
(A) TMCs were incubated with blocking antibodies against CD21, α4, αL, αV, β1 and β2 integrins or 
control antibodies before spinoculation with EBV. After 72 hours GFP expression was measured by 
flow cytometry. (B) Raji cells were incubated with blocking antibodies against CD21, HLA-DR, 
integrins or control antibodies before infection with EBV by spinoculation. Infected cells were 
identified by flow cytometry for GFP. One representative experiment is shown. CTR = control cells, 
only infection. 
 
In Raji cells, antibodies specific for CD21 and HLA-DR showed the highest reduction in 
susceptibility to EBV infection. The antibody specific for CD21 displayed a reduction in 
susceptibility to EBV infection of 60% and HLA-DR 40% (Fig. 6B). The combination of 
these two antibodies resulted in a reduction of susceptibility to EBV infection of 70%. On the 
other hand, antibody specific for α4, αL, αV, β1 and β2 in combination with antibodies 
specific for CD21 and HLA-DR had a minimal effect on susceptibility to EBV infection. 
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Gene-knockdown by transfection of B cells 
To investigate the function of a certain gene, gene-knockdown by RNA interference is a very 
powerful tool. Several methods to deliver siRNA are available, but transfection of B cells is 
very difficult in terms of efficiency and by far not all methods are suitable.  
Because α4 integrin was shown to be involved in EBV entry into B cells and is expressed in 
all cells at a high level (described in chapter 1) we silenced α4 integrin in Raji cells by 
transfection with siRNA against α4 integrin. We tested chemical, physical and viral methods 
to deliver siRNA into B cells.  
 
Chemical methods:  
Chemical transfection is the most commonly used method and was the first method we tested.  
We tested two lipid based transfection reagents, which differed in the charge of the lipids 
forming complexes with the siRNA. The first reagent used (HiPerFect) contained cationic and 
neutral lipids, whereas the second contained only neutral lipids (XtremeGENE). 
 
We transfected Raji cells with HiPerFect (Qiagen), in which the lipid-siRNA complexes were 
delivered in positively charged liposomal vesicles into the cells.  
Transfection of a fluorochrome tagged control siRNA (Alexa Fluor 488) resulted in a 
transfection efficiency of 50% (Fig. 7A). After 24 hours, 48 hours or 72 hours no significant 
and specific down of neither GAPDH (Fig. 7B) nor α4 integrin mRNA (Fig. 7C) was 
achieved in comparison to non-target siRNA.  
 
The second lipid transfection reagent XtremeGENE (Roche) contained only neutral lipids and 
demonstrated only a low transfection efficiency of 7% (Fig. 7D). Moreover, no down-
regulation of neither GAPDH nor α4 integrin mRNA in comparison to non-target siRNA was 
observed (data not shown). 
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Figure 7. Liposome-based transfection of Raji cells. 
Raji cells were transfected with two liposome-based transfection reagents. (A) HiPerFect (Qiagen): 
Raji cells were transfected with Alexa Fluor 488 tagged siRNA. Flow cytometry data illustrate the 
histogram analysis of Alexa Fluor 488. Numbers on the plot indicate the percentage of positive cells 
for Alexa Fluor 488. (B) Raji cells were transfected either with non-specific siRNA or with siRNA 
specific for GAPDH. Results are expressed as 2-ΔΔct. (C) Raji cells were transfected with either non-
specific siRNA or specific siRNA against α4 integrin. Results are expressed as 2-ΔΔct. (D) 
XtremeGENE (Roche):  Raji cells were transfected with a second liposomal transfection reagent. 
Numbers on plot indicate the percentage of positive cells for the Alexa Fluor 488 tagged siRNA. 
 
 
Physical transfection methods:  
Physical transfection methods, like electroporation of magnetofection, are based on delivery 
of exogenous material through the membrane by physical forces. 
We tested two different approaches to evaluate the best physical transfection method, namely 
electroporation and magnetofection. 
1) Electroporation: Electroporation is a widespread method used for molecule delivery into 
target cells. In general, electroporation has been known to be less efficient than other 
methods, especially when compared to viral transfection methods. But, on the other hand, it 
has advantages in terms of the larger capacity of DNA insertion (89). 
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We first determined the optimal electroporation conditions which was defined as the highest 
detection of the Alexa Fluor 488 labeled control siRNA and the highest cell viability rate. 
Electroporation (Neon transfection systems by Life Technologies) of Raji cells resulted in 
high transfection efficiency with the Alexa Fluor 488 tagged control siRNA. As detected by 
flow cytometry, 93% of the cells were positive for the Alexa Fluor 488 siRNA in comparison 
to non-transfected cells (Fig. 8A). To test the efficiency of silencing at the mRNA level we 
transfected a validated siRNA against GAPDH. As measured by RT-PCR, transfection with 
this siRNA resulted in >85% gene silencing compared to non-specific siRNA (Fig. 8B). Thus, 
B cell transfection by electroporation is highly efficient. 
 
 
 
 
 
 
Figure 8. Optimization of electroporation conditions with Raji cells. 
 (A) Raji cells were electroporated (Neon) with the parameters 1325-20-2 (pulse voltage-pulse width-
pulse number). Cells were analyzed by flow cytometry 48 hours after electroporation and data are 
depicted as histogram. Numbers on plot indicate the percentage (%) of positive cells for Alexa Fluor 
488. The parameters 1325-20-2 resulted in the highest percentage of positive cells for Alexa Fluor 
488. (B) Raji cells were transfected with either non-specific siRNA or with siRNA specific for 
GAPDH and the relative transcripts were measured by RT-PCR. Various parameters for 
electroporation were tested and are represented in numbers below the bars. Results are expressed  
as 2-ΔΔct. 
 
2) Magnetofection:  
This technology was first used in 2002 (141) and is based on the use of magnetic 
nanoparticles.  
In order to compare the two physical methods, namely electroporation and magnetofection, 
Raji cells were transfected with siRNA against α4 integrin with both methods in parallel. The 
viability of magnetofected Raji cells was very low (0-5%) (data not shown). This is in 
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contrast to the manufacturer’s information, which states that one of the advantages of 
magnetofection is high cell viability. Efficiency of silencing was tested with siRNA specific 
for α4 integrin in comparison to the mRNA of GAPDH. Electroporation with siRNA specific 
for α4 integrin reduced mRNA expression of α4 integrin by 50%, whereas magnetofection 
with the very same siRNA reduced the α4 integrin expression rate only about 10% (Fig. 9). 
Although the magnetofection experiment was performed only once, the results obtained 
showed that the protocol must be improved. The cell line BJAB was tested as well, but none 
of the cells survived (data not shown). 
 
 
 
Figure 9. Transfection of Raji cells in parallel with electroporation (Neon) and magnetofection. 
Bar graph showing relative α4 integrin transcripts in Raji cells. Raji cells were transfected with siRNA 
specific for α4 integrin or non-target siRNA. The resulting relative transcripts of α4 integrin were 
normalized to GAPDH. Results displayed represent one experiment.  
 
 
Biological methods: Virus-mediated transfection 
Virus-mediated transfection is considered to be highly efficient and is also termed viral 
transduction. We silenced α4 integrin and CD21 in Raji and BJAB cells by viral transduction. 
We generated stable cell lines with Raji and BJAB cells with lentiviruses encoding non-target 
control shRNA, and shRNA targeting B2M (beta 2 microtubulin), α4 integrin or CD21. After 
infection, cells were selected and amplified for five weeks. Non-target or B2M transfected 
cells did not survive, most probably because of insufficient infection by the lentiviruses. Most 
of the Raji cells died rapidly after puromycin selection, indicating an inefficient transfection 
by lentiviruses as well. Therefore, only a few clones could be analyzed by flow cytometry 
(see Fig. 10A and B). Nevertheless, α4 and CD21 cells were analyzed for surface marker 
expression by flow cytometry. 
Integrin α4 protein expression in BJAB and Raji was not reduced in virally transduced cells in 
comparison to parental cells (Fig. 10A). Also the expression of CD21 was not reduced (Fig. 
10B).  
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In summary, an efficient silencing with specific siRNA against GAPDH could be achieved, 
but not with siRNA against α4 integrin. In addition, silencing with shRNA was not efficient, 
but could be possibly improved with changes in the infection procedure. 
 
 
Figure 10. BJAB and Raji cell transduction with lentiviral particles encoding shRNA 
against α4 integrin or CD21.  
BJAB or Raji cells were transduced with lentiviral particles (MOI=4) harboring either pLK0.1 
encoding shRNA against α4 integrin (A) or CD21 (B). α4 integrin or CD21 expression was measured 
by flow cytometry five weeks after viral-mediated transfection. Shown is a representative histogram of 
the cells stained with α4 integrin or CD21 antibody. Wildtype cells stained with specific antibody are 
in black and isotype control in grey. Histograms in heavy lines represent different shRNA sequences 
(S): S1-orange, S2-blue, S3-green, S4-pink, S5-yellow. 
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3) Separation of naïve and memory B cells from tonsils by MACS 
(Magnetic-activated cell sorting)  
In this dissertation (topics 1+2), we characterized integrin expression on several B cell lines 
and showed a novel role of α4 integrin in EBV entry into B cells. In future studies it will be 
interesting to investigate whether the information obtained from B cell lines can be confirmed 
in primary B cells. TBCs are located in the tonsils where the portal of EBV entry is located 
portal of EBV entry is. Therefore, we decided to focus on TBCs. For future investigations of 
the involvement of integrin in EBV infection of TBCs a diversity of different experiments 
will be necessary. Experiments will include RT-PCR or gain-of-function experiments in 
primary B cells and, furthermore, physically separated naïve (CD19+CD27-) and memory 
(CD19+CD27+) B cells will be needed. To separate naïve and memory B cells, we decided to 
use a separation method based on magnetic-activated cell sorting (MACS) MicroBeads. These 
MicroBeads have been developed to separate human B cells and their subpopulations from the 
peripheral blood. The separation of naïve and memory B cells is based on a two-step 
procedure. First, B cells (CD19+) are separated from the leukocytes population by a negative 
separation, whereof memory B cells (CD19+CD27+) are separated with a second step by 
positive separation. 
Non-B cells were labeled with a biotin antibody cocktail including CD2, CD14, CD16, CD36, 
CD43 and CD235a and, thereafter, magnetically labeled with anti-biotin MicroBeads and the 
cell suspension was loaded onto a MACS column. The non-labeled cells (CD19-positive B 
cells) were collected in the flow through (Fig. 11B-D). 
Subsequently, the CD19-postive cells were magnetically labeled with CD27 MicroBeads and 
loaded onto a MACS column. The unlabeled cells run through the column and the CD27-
positive cell fraction was retained in the column. The CD27-positive cells were rinsed from 
the column after removing it from the magnetic field (Fig. 11B-D). After every separation 
step, cells were stained with antibodies against CD19 and CD27 and the purity of the cell 
population was determined by flow cytometry. Gates were set as depicted in Figure 11A. 
In peripheral blood mononuclear cells (PBMCs), the separated memory (CD27-positive) B 
cells were detected by flow cytometry (Fig. 11B). In contrast to PBMCs, no CD27-positive 
cells could be detected in the tonsilar mononuclear cells (TMCs) after separation from the 
CD19-positive cells (Fig. 11C). Separation of CD27-positive cells from TMCs was successful 
after CD19-negative and IgD negative separation (Fig. 11D), but was not verifiable after an 
additional labeling and separation procedure with CD27 MicroBeads. This indicates that 
CD27 MicroBeads might hinder the binding of CD27 antibody to tonsillar memory B cells, 
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but not from the peripheral blood. Thus, separation of naïve and memory B cells from tonsils 
is possible by using the IgD marker. 
 
 
 
Results 
 
 
36 
Figure 11. Separation of memory B cells from tonsils using MACS MicroBeads. 
The memory B cell isolation kit was used for the isolation of memory B cells from PBMCs and 
TMCs. (A) Gates of CD19 and CD27-positive cells were set according to FMO (fluorescence minus 
one) conditions. (B) CD27 memory B cells were isolated from human PBMCS first by depletion of 
non-B cells and subsequent positive selection with CD27 MicroBeads. Cells were stained with 
antibodies against CD19 and CD27. (C) Isolation of CD27 memory B cells from TMCs with CD27 
MicroBeads and cells were stained with antibodies anti-CD19 and CD27. (D) Depletion of non-B cells 
and IgD positive cells was done with TMC and a subsequent separation with CD27 MicroBeads. Cells 
were stained with antibodies against CD19 and CD27. 
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Abstract: 
Lymphoproliferative diseases (LPDs) associated with Epstein-Barr virus (EBV) infection 
cause significant morbidity and mortality in bone marrow and solid organ transplant 
recipients. To gain insight into LPD pathogenesis and to identify potential effective 
therapeutic approaches, we investigated early molecular events leading to B cell 
transformation by gene expression profiling of EBV-infected B cells from tonsils by 
Affymetrix microarray 72 hr postinfection when the B cells hyperproliferation phase starts. 
Cell cycle and apoptosis were the most significantly affected pathways and enriched gene 
sets. In particular, we found significantly increased expression of cyclin-dependent kinase 
(CDK)1 and CCNB1 (cyclin B1) and of one of their downstream targets BIRC5 (survivin). 
Importantly, the strong upregulation of the antiapoptotic protein survivin was confirmed in 
lymphoblastoid cell lines (LCLs) and 71% of EBV-positive post-transplant EBV-LPD lesions 
scored positive for survivin. The validity of early transforming events for the identification of 
therapeutic targets for EBV-LPD was confirmed by the marked antiproliferative effect of the 
CDK inhibitor flavopiridol on LCLs and by the strong induction of apoptosis by survivin 
inhibition with YM155 or terameprocol. Our results suggest that targeting of CDKs and/or 
survivin in post-transplant EBV-LPD by specific inhibitors might be an important approach to 
control and eliminate EBV-transformed B cells that should be further considered. 
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Discussion and Future Perspectives 
 
The α4β1 integrin was first identified as an activation-dependent receptor on hematopoietic 
cells. Research has transformed our understanding of this integrin and demonstrated that α4β1 
integrin is a very dynamic cell surface receptor that mediates several biological activities, in 
particular B and T cell development and prevents GC B cells from undergoing apoptosis.  
 
The work presented in this dissertation shows a novel role of α4β1 integrin in EBV entry into 
B cells. 
An interesting observation is that Raji cells were more susceptible to EBV infection than 
primary B cells. Given that Raji cells and primary B cells show a similar expression level of 
the known EBV receptors CD21 and HLA-DR, we hypothesized that the increased 
susceptibility of Raji cells to EBV infection was due to their higher expression of α4 integrin. 
In particular, recent studies on EBV entry revealed that, depending on the cell type, different 
integrins are involved in viral entry into host cells. So far α3, α5, αV (182) and β1 integrin 
(171, 182) were shown to play a role in EBV infection of polarized epithelial cells, but for B 
cells only α5β1 has been associated with increased infection (43). Enhanced susceptibility of 
Raji cells to EBV infection could also be due to a more abundant expression of CD35, a 
recently described EBV co-receptor in B cells, (121). We confirmed that Raji cells lack CD35 
(121) whereas TBCs did express CD35. Apparently, the absence of CD35 did not seem to 
reduce the susceptibility of Raji cells to EBV infection in comparison to primary B cells that 
express CD35. The higher expression of α4 integrin in Raji cells compared to primary B cells 
suggested that this integrin might indeed favor the infection process of B cells. 
Moreover, overexpression of α4 Integrin in BL cell line Akata31, which is poorly infectable 
with EBV, revealed a solid increase by two-fold in susceptibility to EBV infection. Based on 
these results, the question arises, for which process EBV might employ α4β1: as an 
attachment or post attachment receptor? We propose that the cellular α4β1 can be used as an 
attachment receptor bringing EBV closer to the cell membrane and, simultaneously, might 
induce a possible signaling event in the B cell (Fig. 12-1). Binding of viral pg350/220 to 
CD21 is absent in the model cell line Akata31, but it does take place in B cells expressing 
CD21 (Fig. 12-2). The arising interaction of gp42gHgLgB with HLA-class II induces fusion 
of the viral envelope with the cellular membrane (Fig. 12-3). The question of whether 
integrins are used only as attachment molecule or whether it is necessary as a post-attachment  
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event (internalization, signaling etc.), has been investigated for several viruses. For example, 
HSV-1 was shown to use αVβ3 to fuse with the host cells (55). HCMV interacts with α2β1, 
α6β1, and αVβ3 integrin to induce internalization (47, 177). In the case of EBV it is depended 
on the cell type: for EBV entry into B cells, integrins play a role as co-receptors for 
attachment to B cells. But as for epithelial cells, EBV binds integrins for attachment (74)  and 
internalization (27). 
 
The hypothesis that interaction of EBV and α4 could induce a signaling event in B cells is an 
intriguing idea and further investigation might shed light on the precise function of the 
cooperation of α4 integrin with an EBV receptor. One study reported that binding of α4 
integrin to its natural ligand VCAM-1 activates the downstream signaling and prevents 
apoptosis of GC B cells during their selection process (99). Thus, binding of EBV to naïve B 
cells would induce the α4 Integrin signaling pathway and, for the benefit of EBV, support the 
rescue of EBV-infected B cells.  
To investigate whether EBV itself activates integrin signaling thereby enhancing infection 
efficiency, the phosphorylation state of FAK, PI3K upon binding of EBV to B cells should be 
examined. 
It has been already been shown, that down stream signaling of α5β1 integrin enhances 
infection efficiency in tonsillar memory B cells (43). The initial step in integrin signaling 
involves activation of the fokal adhesion kinase (FAK) followed by downstream signaling 
trough phosphoinositide-3-kinase (PI3K) and the tyrosine-protein kinase Scr (c-Scr). In 
contrast to other alpha subunits, α4 integrin has the ability to induce signaling. The biological 
activities of α4 integrin depend on the cytoplasmatic domain. Proteins interacting with the 
cytoplasmic domain increase cell migration. Paxillin, a signaling adapter protein, binds 
directly to the α4 integrin subunit, but not to most othe cytoplasmic domains. Further 
downsteram, Paxillin directly interacts with several intracellular signaling and adapter 
proteins, such as the focal adhesion kinase (FAK).  
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Figure 12. Putative model of EBV entry into B cells. 
EBV attachment is facilitated via an unknown EBV receptor to the B cell receptor α4β1 integrin (1). 
This interaction brings EBV closer to the cell membrane and induces a possible signaling event (2). 
Subsequently, viral gp350/220 might bind to the cell surface molecule CD21. The interaction of the 
viral gp42/gHgL complex with HLA-class II triggers fusion of viral envelope and B cell membrane 
(3). The depicted interaction of the receptors CD21 and gp350/220 in (2) and (3) are grayed out and do 
not exist in our model cell line Akata31. In primary B cells this interaction certainly happens.  
 
 While gain-of-function experiments revealed an involvement of α4 in EBV entry into 
Akata31 cells, silencing experiments were more difficult to perform in B cells.  
 First, blocking experiments with inhibitory antibodies against integrins expressed on B 
cells did not result in a decreased ability of EBV to infect Raji or tonsillar B cells.  
Nonetheless, the control antibody against CD21 decreased EBV susceptibility to EBV 
infection. Interestingly, not every commercial available inhibitory α-CD21 antibody could 
block EBV binding to B cells. The successful inhibition of EBV entry into B cells preceded a 
testing of different blocking α-CD21 antibodies (data not shown). However, the question 
whether integrins are involved in EBV infection was not solved.  Conclusively, we considered 
the possibility that the commercially available inhibitory antibody was not hindering EBV 
binding to the B cell.  
 Based on these observations, we performed silencing of α4 integrin in Raji cells by 
siRNA. An efficient silencing in Raji cells with siRNA specific for α4 integrin could not be 
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achieved although four siRNA sequences were tested. Therefore, as expected, EBV infection 
of cells treated with siRNA specific for α4 integrin resulted in no difference in susceptibility 
to EBV infection in comparison to wildtype cells. In contrast, silencing with specific siRNA 
for GAPDH showed a reduction of the mRNA level of more than 90%, indicating the correct 
technique was applied for siRNA delivery into Raji cells. Most probably, the sequences are 
not effective in target silencing. In addition, gene knockdown with shRNA encoding α4 
integrin or CD21 was performed. Although five shRNA sequences were tested, there was no 
decrease of protein expression. This was surprising, because lentiviral transduction is usually 
very efficient. An improvement of silencing could probably be achieved with a modified 
protocol. A last try to silence α4 integrin could be conducted with plasmids encoding α4 
integrin shRNA, since transfection of B cells is now well established in our laboratory. 
 
Separation of naïve and memory B cells from tonsils by MACS 
It would be an advantage to test the findings of this dissertation in primary B cells. This 
includes several experiments, such as RT-PCR analysis and overexpression studies. For these 
experiments, it would be very convenient to have separated naïve and memory B cells to 
investigate the subpopulations in terms of different susceptibilities to EBV infection. This can 
be achieved for example by separation by MACS. This technique was developed for 
separation of naïve and memory B cells from the peripheral blood and follows a two-step 
protocol. First, all B cells (CD19+) are separated by a negative selection. In a second step 
memory B cells (CD19+CD27+) are separated from the naïve B cells (CD19+CD27-) by a 
positive labeling of the CD27 marker. The separation can finally be verified by flow 
cytometry analysis for purity.  
 We followed this protocol to separate naïve and memory B cells from tonsils, and the 
first step of CD19+ cell separation was always successful, according to the flow cytometry 
analysis. The CD19+ population reached usually a purity of up to 96%. In contrast, the 
positive separation of memory B cells, failed regularly and CD19+CD27+ cells could not be 
visualized by flow cytometry. The use of different anti-CD27 antibody clones for flow 
cytometry could not solve the problem. Finally, a different way of separating naïve and 
memory B cells was successful. Memory B cells from tonsils could be separated from the 
naïve B cells by an IgD negative instead of a CD27 positive separation. 
In this experimental setup, it might be possible that the MicroBead-coupled anti-CD19 
antibody prevents the binding of the fluorochrome-labeled anti-CD27 antibody, which is 
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normally used in flow cytometry. . However, this explanation does not seem to be very likely, 
since memory B cells from tonsils and the peripheral blood must have a similar phenotype.  
 
The work presented in this dissertation enhances our understanding of the involvement of 
integrin in EBV entry into B cells and demonstrates a novel role for α4 integrin in EBV 
infection of B cells. Additional work is necessary to dissect the role of α4 integrin in other B 
cells, such as the BL cell line BJAB or the LCL derived from a CD21 negative donor. To gain 
a deeper insight into these findings, the direct interaction of α4β1 with EBV could be studied 
by colocalization studies. For this studies an effective staining of α4β1 integrin and EBV is 
necessary. Additionally, it might be interesting to investigate which EBV molecule might be 
involved in tethering of EBV to the B cells while interacting with cellular α4 integrin. 
Investigations of EBV entry receptors, potentially responsible for the entry of EBV into 
epithelial cells, revealed two receptors.  In this context, the viral BMRF2 interacts with α3, α5 
and β1 integrin (74), whereas the receptor gHgL interacts with αvβ5, αvβ6 and αvβ8 (27).  
Investigating the protein sequence of EBV, I found that the viral glycoprotein gp350 
contains a LDV motiv. This acidic peptide motiv was shown to be critical for the mechanism 
of ligand recognition by α4 integrin. Conducting experiments using a recombinant EBV 
containing no gp350 could exhibit whether gp350 plays a role in facilitating EBV entry into B 
cells. And finally, a co-immunoprecipitation could further elucidate existing protein-protein 
interactions. 
While the present study has focused on the analysis of alternative B cell receptors involved in 
EBV entry into B cells, future studies will be necessary to investigate the impact of these 
receptors on B cells upon EBV binding and determined the unknown binding partner for α4 
integrin on the side of EBV. 
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Experimental Infectious Diseases and Cancer Research, University Childrens Hospital of 
Zurich, University of Zurich 
 
 
The γ-herpesvirus Epstein Barr virus (EBV) was demonstrated to infect B cells in a CD21-
dependent and -independent manner. We have previously shown that α5β1 plays a role in 
EBV infection of B cells however the role of other integrins in this process remains elusive. 
We investigated Burkitt lymphoma (BL) cell lines and primary B cells from tonsils (TBCs) 
for their integrin expression. We show here that the BL cell line Raji expresses α4 integrin 
more abundantly than TBCs and is also more susceptible to EBV infection than the latter. 
Moreover, overexpression of the subunit α4 integrin facilitated EBV entry into the EBV-
negative cell line Akata31, but not in the EBV negative cell line BJAB. Our data indicate that 
α4β1 integrin plays a role in the process of B cell infection by EBV and may contribute to 
enhanced susceptibility of B cell subsets to EBV infection thus promoting survival of the 
virus.  
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Introduction 
More than 95% of the human adult population is infected with the gammaherpesvirus 
Epstein-Barr virus (EBV) (24). Upon infection EBV remains life long in a B cell pool since 
the EBV-specific immune response controls primary infection but cannot expulse the virus 
from the body (16, 17).  
EBV is associated with several human cancers including B cell lymphoma and 
nasopharyngeal carcinoma. Moreover, EBV is capable to transform B cells in vitro (1). 
EBV can infect both epithelial cells and B cells but the preferential target cells are B cells. 
The main factors involved in EBV entry into B cells were identified: The viral glycoprotein 
gp350/220 is responsible for EBV attachment to the complement receptor 2 (CR2), the 
cellular CD21 (11, 35). Fusion of EBV with B cells requires the viral glycoprotein gB and the 
tripeptide gHgLgp42. gp42 interacts with HLA class II and triggers fusion of EBV envelope 
and B cell membrane (2, 14, 15, 22, 39). 
Recently, the complement receptor 1 (CD35) was shown to be an attachment receptor for 
EBV on B cells as well but this was restricted to primary B cells and was not found on B-
LCLs and most Tumor cell lines (27).  
 
Although EBV is known to infect B cells without the expression of CD21 (36) little is known 
about the contribution of other cellular receptors to viral attachment or binding on B cells. In 
epithelial cells, which do not express CD21 and HLA class II, integrins were used as triggers 
for EBV fusion. Integrins belong to a large family of transmembrane cell surface receptors 
consisting of a non-covalently linked α and β subunit (31). They serve as adhesion receptors 
and are important for contact to their environment as well as for cell-to-cell communication 
and are therefore attractive candidates for viral attachment (34). The integrins αVβ1, α3β1 
and α5β1 were found to be receptors for EBV on oral epithelial cells (41).  
We previously showed that β1 integrin is involved in conferring a higher susceptibility to 
EBV on memory B cells from tonsils (9). But most probably other integrins were also 
involved in EBV entry into B cells. Several integrins are known to be expressed on B cells. 
αMβ2 was shown to be involved in B cell adhesion to the basolateral membrane of epithelial 
cells during transfer infection of EBV (30). Integrin α6β1 and αVβ1 were exhibited to be 
important during B cell activation of tonsillar B cells (28). αV was demonstrated to be 
expressed at very low levels on primary B cells (18). Additionally, αLβ2, α4β1 and α4β7 are 
crucial for migration and development of B cells (43). Because B cells express a variety of 
integrins, it is of interest to determine their distinct implication in EBV attachment on B cells. 
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Our findings demonstrate that α4 integrin, which is expressed in most B cell lines facilitates 
EBV entry into the EBV negative cell line Akata31 but not in the EBV negative cell line 
BJAB. Our data indicate that α4 integrin together with β1 plays a role as receptor for EBV 
entry into host cells when CD21 is absent but most possibly also to tether EBV closer to the B 
cell membrane. 
 
 
Results 
 
Susceptibility of autologous tonsillar and peripheral blood B cells to EBV infection 
In our previous study (10) we compared the susceptibility of naïve and memory B cells from 
tonsil (TBCs) to EBV infection in vitro with that of their counterparts in peripheral blood 
(PBBCs). Nevertheless, we did not compare the susceptibility of TBCs and PBBCs to EBV 
infection from autologous donors and we used a recombinant EBV strain with a latenet 
membrane protein 2 (LMP2) deletion after insertion of the green fluorescence protein (GFP) 
gene (32, 33). Therefore, we investigated whether autologous TBCs and PBBCs follow the 
same pattern of infection after exposure to a BAC-recombinant EBV wt in vitro as in the prior 
study. EBV wt has the advantage of being derived from wild type EBV and has no gene 
deletion (7).  
To this end, autologous TBCs and PBBCs from three EBV-seronegative and two EBV-
seropositive individuals were spinoculated for one hour with EBV (MOI=1.8). 72 hours post 
inoculation cells were stained with antibodies against CD19 and CD27 and naïve 
(CD19+CD27-) and memory (CD19+CD27+) B cells expressing GFP were identified by flow 
cytometry. We found that memory TBCs were similarly often infected with EBV as their 
naïve counterparts (3.9% ±2.6 vs.1.29%±1.1; P > 0.05; Fig. 1). In peripheral blood we found 
also no difference in frequency of EBV infection between naïve and memory B cells (5.1% 
±2.0 vs. 5.3% ±2.4; Fig. 1). These results suggest a similar susceptibility to EBV infection for 
naïve and memory B cells from autologous tonsils and peripheral blood, respectively. This 
finding stands in contrast t o our previous report (10), where EBV with a LMP2 deletion was 
used. In our previous study memory B cells from peripheral blood were less susceptible to 
EBV infection compared to their naive counterparts whereas memory and naïve B cells from 
tonsil were similarly susceptible to EBV infection (9). Thus, the present study demonstrated 
that memory and naïve B cells from TBCs and PBBCs are equally susceptible to EBV when 
using autologous samples and an EBV strain without LMP2 deletion.  
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Establishment of a primary B cell-independent in vitro model to study EBV infection of 
B cells 
Above-mentioned experiments revealed a rather remarkable variation of the B cell 
susceptibility to EBV infection between donors, as reflected by the rather large standard 
deviation of the frequencies of EBV-infected cells after exposure to EBV (Fig. 1). This 
suggests that for further investigation of potential additional receptors for EBV a more 
uniform model of infection would be preferable. We reasoned that using a B cell line to 
model cellular EBV infection might ensure more uniform and robust results. Thus, we 
embarked in searching for a B cell line, which exhibits similar expression of the main entry 
receptors for EBV as TBCs, i.e., CD21 and HLA-DR.  
To this end, we characterized BL cell lines including Raji, Daudi, BJAB, Ramos, Akata31, 
Mutu I, BL2, Akata, the lymphoblastoid cell line L2, and TBCs for the expression of CD21 
and HLA-DR and in addition of the recently reported EBV receptor CD35 (27) by flow 
cytometry. All BL cell lines expressed CD21 and HLA-DR (Table 1). The percentages of 
CD21 positive cells were similarly high in Raji (99.1%), Daudi (94.7%), Ramos (91.4%), L2 
(88.7%) and Akata Takada (98.2%) in comparison to TBCs (98.3%), whereas less BJAB cells 
(75.6%) and only a minority of Akata31 cells (5.4%) were CD21 positive. The BL cell line 
Raji showed the highest Mean Fluorescence Intensity (MFI) of CD21. The percentages of 
HLA-DR positive cells were in all BL cell lines and TBCs equally high. Only TBCs were 
positive for CD35, which was also confirmed by Ogembo et al. (27). These data suggest that 
CD21 is expressed on all BL cells at various levels and HLA-DR is expressed at uniformly 
high levels. 
 
Integrins may possibly function as receptors contributing to EBV infection susceptibility (5, 
9, 37). To first have an overview of integrins expressed in B cells, we characterized the 
expression of α and β integrin subunits at the RNA level by real-time PCR in TBCs and the 
BL cell lines Raji, Daudi, BJAB, Ramos, Akata31, MutuI, BL2, Akata Takada, and the 
lymphoblastoid cell line L2 (supplementary 1 and Fig. 2). Seven alpha (Fig. 2A) and four β 
integrin subunits (Fig. 2B) were analyzed for their presence in TBCs, Raji, BJAB and 
Akata31  (αL, αM, αV, α3, α4, α5, α6, β1, β2, β7). α3 integrin is known to be expressed by 
epithelial and endothelial cells (40). Integrins exist as noncovalently linked α and β subunits 
which pair to heterodimers and on B cells they associate as αVβ1, α5β1, α4β1, α6β1, αLβ2 
and αMβ2.  
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In the following experiments BL cell lines with differential expression of CD21 (Table 1) that 
were compared to TBCs were selected. 
 
TBCs were separated from mononuclear cells by negative selection using micro beads 
(MACS). The purity of the separated CD19+ cells was > 96%, as determined by flow 
cytometry (data not shown). 
In Figure 2 we compared the expression of integrins in TBCs to that in Raji, BJAB and 
Akata31. We found that two integrins αLβ2 and α4β1 were highly expressed in TBCs and to a 
lower extent also in Raji, BJAB and Akata31 (Fig. 2). α5β1 and αMβ2 integrin were 
expressed at a very low level and only in TBCs. Integrins α3β1 and α6β4 were detected at 
very low mRNA levels in TBCs and the three BL cell lines. 
In summary, TBCs expressed the highest levels of integrins and predominantly αLβ2 and 
α4β1. 
 To validate the obtained mRNA data we analyzed the integrin expression at protein 
level by flow cytometry. Integrins, which were hardly detectable at mRNA level and thus 
assumed to have no expression on B cells like β4, α3 and αE integrin were excluded. TBCs, 
Raji, BJAB and Akata31 cells were stained with antibodies against integrins αL, αV, α4, α5, 
α6, β1, β2 and β7 detected by flow cytometry (Fig. 3). 
 
TBCs expressed all examined integrins, whereas BL cell lines displayed integrins in varying 
degrees (Table 2). β1 and α6 integrin were expressed by all cell lines and TBCs (>65% and 
17-38% respectively). β2 integrin was expressed by all cell lines and TBCs (67-99%) but 
Akata31.  
TBCs expressed αL and α5 integrin in >12%. BJAB cells were the only non-primary B cells 
that expressed αL integrin (52%). αV integrin was expressed in TBCs (7%) and BJAB cells  
(11%). Solely TBCs expressed β7 integrin.  
α4β1 was expressed in all cell lines but Akata31. Of note is that the very susceptible cell line 
Raji expressed high levels of α4β1, whereby this integrin is absent in Akata31. 
 
Susceptibility of B cells to EBV infection correlates with integrin expression pattern 
Next, we functionally investigated the susceptibility of BL cells to EBV infection in 
comparison to TBCs. Thus, cells were inoculated with GFP-tagged EBV (MOI = 8), and 72 
hours post inoculation cells were analyzed by flow cytometry for GFP expression. 6% of 
TBCs, 18% of BJAB, 24% of Raji and 3% of Akata31 cells were positive for GFP (Fig. 4). 
Manuscripts 
 
 
61 
Hence, Raji cells were the cells most susceptible to EBV infection, followed by BJAB, TBCs 
and Akata31 cells. Thus, given that Raji cells expressed very frequently α4 integrin (97%), 
which was also expressed in BJAB cells or TBCs, we hypothesized a possible role for α4 
integrin in EBV entry into B cells. 
 
Complexation of divalent cations reduces susceptibility to EBV infection 
Integrin interactions with extracellular ligands are dependent on divalent cations, including 
Ca2+, Mn2+ and Mg2+ (19). The divalent chelator ethylenediaminetetraacetic acid (EDTA) 
alters affinity in integrin-ligand binding by complexing divalent cations, which has been 
shown to reduce binding of integrins to viruses (19). 
Therefore, we investigated the effect of EDTA on susceptibility of Raji cells to EBV 
infection. Raji cells were chosen due to their high susceptibility to EBV infection and similar 
expression of CD21 and HLA-DR as TBCs. This would therefore best allow to screen for the 
potential role of integrins in enhancing cellular EBV infection. Raji cells were incubated with 
increasing concentrations of EDTA and subsequently spinoculated with an EBV at a MOI=5. 
After 72 hours, Raji cells were analysed for GFP expression by flow cytometry. EDTA 
diminished EBV infection in Raji cells in a dose-dependent manner. The blocking effect of 
EDTA on EBV infection between control cells and cells treated with the highest 
concentration was 20% (Fig. 5A).  
Earlier we showed that inhibitory antibodies against CD21 and HLA-DR reduced the level of 
susceptibility to EBV infection of primary B cells up to 80% (9). A complete inhibition, 
however, was not achieved, suggesting additional receptors might be involved in EBV entry 
into B cells. The 20% of EDTA blocking effect would fill the gap and complete the missing 
unknown receptor. We next sought to determine whether additional incubation with EDTA 
could further reduce the already decreased level of susceptibility to EBV infection by 
inhibitory antibodies. Therefore Raji cells were incubated with EDTA or EDTA and 
inhibitory antibodies against CD21 and HLA-DR or both. After 72 hours, cells were preceded 
to flow cytometry analysis for GFP expression. Application of inhibitory antibodies alone 
reduced the susceptibility to EBV infection of about 42% (α-HLA-DR), 55% (α-CD21) or 
80% when combining both antibodies, whereas the additional incubation with EDTA did not 
exhibit any further reduction of EBV susceptibility to EBV infection. Since incubation of 
antibodies and EDTA from Figure 5B resulted in inappropriate conditions for EDTA, the 
perfect conditions must be further established. 
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Thus, we could show that EDTA exerts an inhibitory effect on EBV infection, which 
emphasizes the potential involvement of integrins in EBV infection of B cells.  
 
Effect of reduced expression of α4 integrin on susceptibility to EBV infection  
To determine whether reduced expression of α4 integrin reduces B cell susceptibility to EBV 
infection, we established α4 integrin silencing in Raji cells by use of siRNA. Transfection of 
Raji cells with the fluorochrome-tagged control siRNA showed a transfection efficiency of 
93% in comparison to non-transfected cells (not shown). To test the efficiency for siRNA-
based silencing in Raji cells we employed first a validated siRNA for GAPDH. Transfection 
with the GAPDH-specific siRNA reduced mRNA level of 85 % in comparison to non-specific 
siRNA (not shown). Transfection of siRNA against α4 integrin using one distinct single 
sequence (S1) or the pool of four sequences reduced mRNA levels by about 75% and 50%, 
respectively (Fig. 6A).  
 
To further examine the modest silencing efficiency, transfected Raji cells were stained for  
α4 integrin at the cell surface and expression was analysed by flow cytometry. Use of α4-
specific siRNA reduced protein expression by 10% or 25% 24 hours or 48 hours post 
transfection, respectively (Fig. 6B). 
 
To determine whether the limited reduction of α4 integrin expression would affect 
susceptibility to EBV infection, we transfected Raji cells with siRNA specific for the 
sequence S1 against α4 integrin. 
48 hours post transfection Raji cells were spinoculated with EBV (MOI = 8) and incubated 
for another 48 hours. Thereafter, cells were analyzed for GFP expression by flow cytometry 
(Fig. 6C). The α4 integrin-specific siRNA did not exhibit any inhibitory effect on EBV 
infection as compared to non-specific siRNA (Fig. 6C). We speculate that the silencing effect 
of siRNA was not sufficient enough to reduce cell surface expression of α4 integrin below a 
critical level to reduce the efficiency of EBV infection.  
 
 
 
 
 
Manuscripts 
 
 
63 
Overexpression of α4 integrin in Akata31 cells results in higher susceptibility to 
infection with EBV  
We showed that Akata31 cells are poorly susceptible to EBV infection. Their expression of 
CD21 and α4 integrin is very low.  Thus, the potential role of α4 integrin in EBV infection 
can be examined by overexpression of the integrin in Akata31, especially considering the 
absence of CD21 in this cell line.  
To determine whether gain of function of α4 integrin alters the susceptibility to EBV infection 
in Akata31 or in the more susceptible BJAB cells, we transfected an expression plasmid 
encoding α4 integrin and empty vector. Wt cells and empty vector transfected cells were used 
as controls. As determined by Western blot analysis, α4 integrin expression was highly 
increased in empty vector cells or parental cell line (Fig. 7A). To verify that the expression 
level of other integrins on the cell surface was not altered by overexpression of α4 integrin we 
analyzed the expression of key integrins by flow cytometry. 
 
The percentage of expression and the mean fluorescence intensity (MFI) of all investigated 
integrins were not altered except of α4 and β1 integrin in Akata31 cells (Fig. 7B) and BJAB 
cells (Fig. 7C). In Akata31 cells overexpressing α4 integrin, the percentage of cells expressing 
α4 integrin increased from 0 up to 100% and in BJAB from 10 to 80%. The expression level 
and intensity of CD21 and HLA-DR on Akata31 (Fig. 7D) and BJAB (Fig. 7E) was not 
affected. Hence overexpression of α4 increased surface expression of α4β1 but not any other 
investigated receptor. 
 
To determine whether increased α4β1 integrin expression alters the susceptibility of Akata31 
or BJAB cells to EBV infection, cells were incubated with the GFP recombinant EBV.  
Figure 8A and B show dot plots depicting the expression of α4 integrin in wt, empty vector 
control (EV) and stable transfected cell lines (+α4) in Akata31 and BJAB. Expression of α4 
integrin in Akata31 cells increased their susceptibility to EBV infection by two-fold whereas 
in BJAB cells no such an effect was observed (Fig. 8C and D). This data suggests that α4 
integrin over expression on CD21-negative cells promotes EBV attachment on B cells. The 
data further suggest that α4β1 integrin inherits partially the role of CD21 in the CD21-
negative cell line Akata31. 
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Discussion 
 
In this study we aimed at investigating the potential role of integrins other than α5β1 integrin 
in enhancing the susceptibility of B cells to infection with EBV. We show that (i) Raji cells 
which express more α4 integrin than primary B cells from tonsils are more susceptible to 
EBV infection than the latter; (ii) treatment of Raji cells with EDTA that inhibits the action of 
integrins reduced their susceptibility to EBV infection; and (iii) Akata31 cells which lack α4 
integrin were less susceptible to EBV infection than primary tonsillar B cells but were 
rendered more susceptible to EBV infection by overexpression of α4 integrin. Our 
observations suggest that α4 integrin is involved in the process of B cell infection by EBV 
and may contribute to enhancing susceptibility of B cell subsets that may promote survival of 
the virus. 
 An intriguing observation in our study was that Raji cells were more susceptible to EBV 
infection in vitro than primary B cells. Given that Raji cells and primary B cells express 
similar levels of the main known receptors for EBV, i.e. CD21 and HLA-DR, we 
hypothesized that the increased susceptibility of Raji cells can be attributed to their markedly 
higher expression of α4 integrin compared to primary B cells. Notably, recent studies on EBV 
entry revealed that, depending on the cell type, different integrins are involved in viral host 
cell entry. In polarized epithelial cells α3, α5, αV (41) and β1 integrin (37, 41) have been 
shown to play a role in EBV infection, whereas in B cells only α5β1 (9) was shown to be 
involved. The difference between Raji cells and TBCs is unlikely due to an even more 
abundant expression of the recently described EBV receptor in B cell, i.e. CD35, since we 
confirmed that CD35 is absent n Raji cells (27). Thus, absence of CD35 did not seem to 
reduce susceptibility to EBV infection in comparison to primary B cells that express CD35. 
Instead, the more marked expression of α4 integrin compared to primary B cells suggested 
that this integrin might indeed be involved in the B cell infection process. 
 Our finding that treatment of Raji cells with EDTA resulted in reduced susceptibility of 
Raji cells to EBV infection further underscores that integrins may indeed be involved in EBV 
infection of B cells. Nevertheless, treatment of cells with the divalent cation complexer 
EDTA plus blocking of CD21 and HLA-DR by the use of inhibitory antibodies did not result 
in a complete inhibition of EBV infection. (This experiment will be repeated, since the 
experiment was done only once and the ideal protocol was not established yet). However, a 
possible additive effect of CD21 or HLA-DR blocking antibodies and EDTA to inhibit 
integrins still has not been investigated in detail. Impossible to establish efficient silencing of  
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 An important observation pointing to the role of α4 integrin in enhancing susceptibility of B 
cells to EBV infection was that Akata3 cells overexpressing α4 integrin exhibited a two-fold 
higher susceptibility to EBV infection than parental wild type Akata31 cells. This is 
especially intriguing since we showed here that Akata31 cells do not express CD21. Thus, α4 
integrin does not seem to need collaboration with CD21 but is capable to enhance 
susceptibility to infection by its own. In this regard α4 integrin likely acts as an attachment 
receptor, however further investigation is required to determine the contribution of active α4 
integrin signaling. A study demonstrated that interaction of α4β1 integrin on germinal centre 
(GC) B cells with its ligand VCAM-1 could prevent the cells from undergoing apoptosis. This 
suggested that activation of the α4 integrin pathway may contribute to the B cell selection 
process (20). The result of induced GC B cells by α4 binding via EBV exhibited an 
evolutionary advantage to naïve B cells in preventing EBV infected B cells from apoptosis 
and thus shifts the survival rate in favor of EBV infected cells.  
Use of host cell signaling to enter target cells by viruses and therefore establishing a 
productive infection, was documented for the herpes virus Kaposi sarcoma herpesvirus 
(KSHV). KSHV activates the FAK, Src, PI3K, Rho-GTPases as well as several other 
downstream effector molecules, initiating actin rearrangements that lead to the internalization 
of KSHV (4).  
Likewise, EBV was shown to activate integrin signaling and thereby enhances infection 
efficiency in memory B cells from tonsils. Binding via its glycoprotein BMRF-2 to α5β1 EBV 
initiates FAK, Scr and PI3K to finally activate the actin cytoskeleton (9).  
Furthermore, the access to α4 by EBV might be even promoted by an association of α4β1 
integrin with CD81. It was shown that CD81 could associate with α4β1 integrin in cell 
surface clusters on B cells and promotes cell processes (25). This is also the case for KSHV, 
where integrins associate with other receptors, such as CD98 and thus may form an entry 
complex (12, 38).  CD98 was also demonstrated to be involved in the post entry stage of 
KSHV infection, most probably by mediating a signaling cascade that is important for viral-
gene expression (38). 
Integrins are cell surface receptors, involved in signaling and cell adhesion. Dependent on the 
associated β subunit, α4 integrin may preferentially bind to the vascular cell adhesion 
molecule 1 (VCAM-1) or the mucosal vascular addressin cell adhesion molecule 1 (MadCam-
1). VCAM-1, which is mainly responsible for the recruitment of α4β1 high expressing cells, 
contributes to lymphocyte homing to oropharynx and BALT (42) and hence to the portal of 
Manuscripts 
 
 
66 
EBV spreading. Thus, EBV positive B cells expressing α4β1 are likely to return to the 
oropharynx from where the virus can be transmitted via saliva to other recipients. 
 The results presented here do not define the precise step in EBV cell entry mediated by 
α4 integrin. EBV could use α4 which we showed associates preferentially with β1 integrin, 
essentially as an attachment receptor on B cells or as signaling factor after viral attachment, or 
both. Additionally, the structural EBV capsid protein interacting with α4β1 integrin remains 
elusive. Further studies aiming at elucidating the direct association of EBV with α4 integrin 
will provide inside into these questions. A further limitation was found in approaches to 
diminish expression of α4 integrin subunit in B cells by RNA interference. B cells are highly 
resistant to conventional transfection methods (e.g. cationic lipids and polymers) (13, 26) but 
can be transduced in vitro by electroporation. Achievement of reduced α4 integrin expression 
with specific siRNA against α4 integrin in Raji cells was poor and consequently a reduction 
of EBV infection was not observed. Since the transfection with electroporation was very 
efficient (not shown), and half-life of integrin protein in cultured cells (fibroblasts) is about 6-
18h (6, 23) we suggest a siRNA design problem to cause an insufficient silencing. 
 Our results indicate that α4β1 integrin contributes to enhanced susceptibility of B cells 
to infection with EBV. This may be beneficial for EBV transmission to other hosts, as 
infected B cells expressing α4β1 integrin are likely to home to the oropharynx and BALT, the 
portal of exit of EBV. 
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Material and methods 
 
Cell culture and virus. 
All B cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) 
(Invitrogen, Basel, Switzerland), 1% L-glutamine, and 1% penicillin-streptomycin (from 
Gibco, Basel, Switzerland) in a humidified 5% CO2 atmosphere at 37°C. 
Primary B cells derived from tonsil. All B cell lines originate from Burkitt Lymphoma 
biopsies. The cell lines Raji, Daudi are EBV positive and BJAB, Akata31 and Ramos are 
EBV negative. 
HEK 293 cells carrying stably wildtype EBV BAC (D2089; EBV-wt B95.8)) (kindly 
provided by Henri Jacques Delecluse (DKFZ, Heidelberg, Germany) have been previously 
described (7), Cells were maintained in DMEM, 10% fetal bovine serum (FBS), 1% L-
glutamine, 1% penicillin-streptomycin and 100 µg/ml Hygromycin (LabForce, Nunningen, 
Switzerland). 
 
Antibodies and reagents. 
Anti- CD19 mAb pacific blue (PB)-LT19 (AbD Serotec, Düsseldorf, Germany), anti-HLA-
DR mab APC/Cy7-L243 (Biolegend, San Diego, United States) anti-CD27 mAb 
phycoerythrin (PE)-L128 (BD Bioscience, Allschwil, Switzerland), anti-integrin α4/CD49d 
mAb (PE)-9F10, anti-integrin α5/CD49e mAb (PE)-IIA1, anti-integrin β1/CD29 mAb (PE)-
MAR4, anti-integrin β2/CD18 mAb (PE)-6.7 (all from BD Bioscience, Allschwil, 
Switzerland). Anti-integrin β7 mAb (PE)-473207, anti-integrin αV/CD51 mAb (PE)-P2W7, 
anti-integrin αL/CD11a mAb (PE)-345913 (R&D systems, Abingdon, UK), anti-integrin 
α6/CD49f mAb (PE)-3H1512 (US Biological, Massachusettes, United States .  
Anti-α4 integrin antibody for western blot was purchased from cell signalling (Boston, United 
States). 
 
Isolation of primary cells.  
Human mononuclear cells were separated from tonsils of donors undergoing routine 
tonsillectomy. Preparation of tonsillar mononuclear cells was done as previously described 
(21). 
 
Virus preparation and infection. 
Free virus in supernatant was achieved from induced 293/EBV-wt cells. 293 cells at 80% 
confluency were transfected in 100 mm Petri dish with expression plasmids (5 µg each/dish) 
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encoding the BZLF1 and the BALF4 gene products, using liposome-based reagent 
Metafectene (Biontex, Martinsried/Planegg, Germany). After 5 hours, the transfection 
mixture was removed and cells were kept in DMEM supplemented with 10% fetal bovine 
serum (FBS), 1% L-glutamine, and 1% penicillin-streptomycin. Three days post virus 
induction, virus supernatant was filtered trough a 0.45 µm pore size filter and stored at 4°C 
until use. 
Determination of infectious EBV particles was done like described in (8). 
B cells were inoculated or spin inoculated. B cells were then maintained in supplemented 
RPMI.  
For spinoculation, cell suspension was centrifuged for 1 hour at 800 x g at 4°C. Cells were 
subsequently washed in phosphate-buffered saline and resuspended in fresh complete 
medium. 
For concentration of virus filtrated viral supernatant was centrifuged at 30’000 x g for  
2 hours at 4°C and than resuspended in 1x PBS and stored at 4°C until further use. 
 
Blocking experiments:  
  - with EDTA: 2 x 105 Raji were used. Dilutions of EDTA were prepared in serum free 
RPMI (+ Glutamine and + Pen/Strep.) (50mM, 25mM, 12mM, 5mM, 2.5mM, 1.2mM, 
0.6mM, 0mM). EDTA-dilutions or medium alone was added to wells in triplicate. Cells were 
incubated at 37°C for 90 min, followed by incubation at 4°C for 30 min. 
EBV-wt (MOI=8) was added to the cells, and were spinoculated (800g x for 60 min at 4°C). 
Immediately thereafter medium was replaced and cells were incubated for 72 hours at 37°C.  
Cells were washed and analyzed by flow cytometry. 
 - with inhibitory antibodies and EDTA: To 2 x 105 Raji cells 10 µg/ml of α-CD21 and 
or α-HLA-DR antibody and 25 mM EDTA was added and incubated for 1h at 4°C. followed 
by incubation at 4°C for 30 min. EBV-wt (MOI=8) was added to the cells, and were 
spinoculated (800g x for 60min at 4°C). Immediately thereafter medium was replaced and 
cells were incubated for 72 hours at 37°C.  Cells were washed and analyzed by flow 
cytometry. 
 
Real-time polymerase chain reaction (RT-PCR). 
Total RNA isolation, DNAse treatment, reverse transcription and RT-PCR were performed as 
described earlier (21, 29). 
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qPCR was performed for the subunits α3, α4, α5, α6, αE, αL, αM, αV, β1, β2,  β4 and  β7 and 
integrin expression was normalized to the expression of the housekeeping gene 
hydroxymethylbilane-synthase (HMBS) and further normalized to control (depicted as 2-ΔΔct). 
Total RNA was isolated after 24 hours post splitting the cells. 
All subunits and HMBS were analyzed using primer/probe on demand (Assay-on-demand 
gene expression product; Life Technologies Europe B.V., Zug, Switzerland). 
 
Plasmid integration. 
Transfections were performed with electroporation Neon system (Life Technologies Europe 
B.V., Zug, Switzerland) according to the manufacturer’s instructions.  
24 hours prior to transfection, cells were splitted. 
Akata31 (1150-20-2) or BJAB cells (1350-20-1) (pulse voltage-pulse width-pulse number) 
were transfected with 2.5 µg of α4 integrin plasmid and control pcDNA3.1- (no insert). After 
48 hours, cell culture media was exchanged with media containing 800 mg/ml G418 sulfate. 
Four weeks later, cells were stained with corresponding integrin antibody and integrin surface 
expression was determined by flow cytometry.  
Anti-Phycoerythrin (PE) Microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) were 
used for positive selection of α4 integrin positive labelled (PE) cells according to 
manufacturer’s instructions.  
 
Flow cytometry.  
Flow cytometry was performed using a FACS Canto II flow cytometer (Beckman Coulter, 
Nyon, Switzerland). Flow cytometry data were analysed by FlowJo. 
 
Western blot analysis. 
Cells (1 x 106/ ml) were lysed in lysis buffer (RIPA). Lysates were frozen at -20°C, thawed 
and centrifuged at 10’000 rpm for 10 min at 4°C. Supernatant was mixed with Roti load (Carl 
Roth, Karlsruhe, Germany) and boiled at 96°C for 5 min. Proteins were separated by SDS-
PAGE and transferred to a nitrocellulose membrane (Whatman, GE Healthcare Europe 
GmbH, Switzerland) and visualized using specific antibody and ECL (GE Healthcare Europe 
GmbH, Switzerland). 
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Knockdown of α4 integrin expression with siRNA. 
Raji cells were splitted 24 hours before transfection. At day of transfection, Raji cells were 
mock transfected or transfected with α4 integrin specific or control siRNA (50 mM)(Qiagen 
Allstars Negative Control siRNA) using Neon transfection systems (Life Technologies, Zug, 
Switzerland). After 48 hours of transfection, cells were harvested for detection of surface 
integrin expression by flow cytometry.  
For analysis of infection efficiency, siRNA transfected cells were spinoculated with 
recombinant EBV wt 48 hours post transfection. After 48 hours cells were harvested and 
infection rate was determined by flow cytometry. 
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Tables and Figures 
 
 
Table 1 
 
Cells CD21 [%] CD21 [MFI] HLA-DR [%] HLA-DR [MFI] CD35 [%] CD35 [MFI] 
TBCs 98.3±1.4 16’935±1’242 98.4±0.2 30’705±2’770 19±10 1447± 281 
Raji 99.1±0.3 57’434±7’907 95.2 48’805±5’632 n.d. n.d. 
Daudi 94.7±0.4 5’416±623 99.4±0.3 43’891±5’990 n.d. n.d. 
BJAB 75.6±2.6 2’147±223 99.7±0.2 27’022±3’201 n.d. n.d. 
Ramos 91.4±1.8 4’689±518 98.89±0.2 14’212±2176 n.d. n.d. 
Akata31 5.3±1.2 2’691±303 97.4±0.5 85’746±10’427 n.d. n.d. 
Mutu I 85±1.2 4’856±489 99.3±0.3 54’420±7’702 n.d. n.d. 
BL2 96 1’149±98 97.4±0.5 44’789±7’517 n.d. n.d. 
L2 88.7±1.8 8’744±1’593 98.6±0.5 54’290±9’257 n.d. n.d. 
Akata 98.2±1.3 5’867±781 99.1±0.2 40’278±6’257 n.d. n.d. 
 
 
Table 1. Presence of main receptors for EBV entry on various B cells. 
TBCs, Raji, BJAB, Ramos, Akata, Akata31, Mutu I, BL2 and L2 were specifically labelled 
with monoclonal antibodies against CD21, HLA-DR and CD35.  
The percentage of stained cells was quantified by flow cytometry. Shown are the percentages 
of positive cells and the numbers in the right column are the corresponding mean fluorescence 
intensity (MFI). 
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Table 2 
 
 
 
 
Table 2. Integrin protein expression of TBCs, Raji, BJAB and Akata31. 
TBCs, Raji, BJAB and Akata31 were specifically labelled with monoclonal antibodies against 
the integrin subunits αL, αv, α4, α5, α6, β1, β2 and β7. The percentage of stained cells was 
quantified by flow cytometry. Numbers are the percentage of positive cells and the number on 
the right is the corresponding MFI. The results derived from three independent experiments. 
n.d. means not detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Integrin TBCs Raji BJAB Akata31 
αL 18% 
± 5 
4347 
±3940 
n.d. 52% 
±4 
2638 
±270 
n.d. 
αV 7% 
± 5 
2320 
±1341 
n.d. 11% 
±4 
1157 
±434 
n.d. 
α4  49% 
±15 
8372 
±7254 
98% 
±2 
12197 
±3567 
42% 
±16 
1419 
±950 
n.d. 
α5 12% 
± 9 
480 
±286 
n.d. n.d. 12% 
±1 
791 
±306 
α6 38% 
±15 
1825 
±621 
30% 
±22 
1968 
±618 
33% ±4 1423 
±2005 
17% 
±4 
1063 
±677 
      
β1 65% 
±12 
6462 
±5626 
100% 
±1 
9041 
±3187 
98% 
±3 
5206 
±2150 
76% 
±14 
1676 
±1169 
β2 99% 
±1 
2642 
±865 
67% 
±42 
2236 
±1410 
96% ±2 6137 
±2462 
n.d. 
β7 9% 
±4 
830 
±648 
n.d. n.d. n.d. 
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Figure 1 
 
 
 
 
 
Figure 1. In vitro infection of autologous tonsillar and peripheral blood B cells. 
Mononuclear cells were harvested from tonsils and isolated by Ficoll-Hypaque density 
gradient centrifugation. Subsequently the cells were spinoculated with EBV, MOI=1.8. After 
72 hours, cells were stained for CD19 and CD27 and analyzed by flow cytometry. The bars 
represent the naïve (CD19+CD27-) and memory (CD19+CD27+) B cells positive for GFP. 
Data derives from five autologous donors as means ± standard deviation (SD). 
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Figure 2 
 
 
 
Figure 2. Comparison by quantitative real-time PCR of integrin mRNA expression in 
primary B cells, Raji, BJAB and Akata31 cells. 
Expression level of selected integrins was determined using real-time PCR. mRNA 
expression is shown of seven α  (A) and four β subunits (B). The real-time PCR data was 
expressed as mRNA levels relative to hydroxymethylbilane synthase (HMBS). Depicted are 
values as 2-Δct. 
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Figure 3 
 
 
 
 
 
Figure 3. Integrin protein expression of TBCs, Raji, BJAB and Akata31. 
TBCs, Raji, BJAB and Akata31 were specifically labelled with monoclonal antibodies against 
the integrin subunits αL, αv, α4, α5, α6, β1, β2 and β7. Grey shadow represents isotype 
control and solid line the integrin expression. 
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Figure 4 
 
 
 
Figure 4. Infection frequency of TBCs, Raji and Akata31. 
Freshly isolated TBCs, Akata31, Raji and BJAB were inoculated with EBV (MOI=8) and 72 
hours post inoculation cells were analysed for GFP by flow cytometry. The graph represents 
the percentages of GFP positive cells.  
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Figure 5 
 
 
Figure 5. EDTA decreases EBV infection in a dose dependent manner. 
(A) Raji cells and EBV were incubated with different concentration of EDTA (0.6 mM, 1.2 
mM and 2.5 mM) for 90 min at 37°C following incubation at 4°C for 30 minutes. EBV  
(MOI=5) was spinoculated with the cells. Infected cells were identified by flow cytometry. 
CTR means EDTA untreated cells. Results are represented as means ± SD.  
(B) Raji cells were incubated with antibodies against CD21 (10 µg/ml), HLA-DR (10 µg/ml), 
or both prior EBV infection and subsequently EDTA was added (2.5 mM). Infected cells were 
identified by flow cytometry. CTR cells were calculated as 100%. White bars: addition of 
blocking antibodies; black bars: addition of EDTA and blocking antibodies. 
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Figure 6 
 
 
 
Figure 6. Diminished expression of α4 integrin with siRNA does not decrease EBV 
susceptibility of Raji cells. 
(A) Raji cells were transfected with non-specific control siRNA or either with distinct single 
sequence siRNA (S1) for α4 integrin or a pool of four sequences. Results are expressed as 
mRNA levels relative to HMBS 48 hours after transfection. (B) Raji cells transfected with 
either distinct siRNA (black heavy line) for S1 (left) and pool (right) or with non-specific 
control siRNA (grey shadow) were stained with antibody against α4 integrin. Transfected 
cells were identified by flow cytometry for α4 integrin after 48 hours. Dotted line represents 
isotype control. 
(C) Raji cells were transfected with non-specific control siRNA or with distinct siRNA 
against α4 integrin. After 48 hours cells were spinoculated with EBV. Flow cytometry 
analysis for GFP was done after additional 48 hours. 
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Figure 7 
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Figure 7. Over expression of α4 integrin in Akata31 and BJAB. 
Akata31 and BJAB cells were transfected with a plasmid encoding α4 integrin or empty 
vector. (A) Protein from whole Akata31 lysate was separated by SDS-PAGE and analyzed by 
Western blot with anti-α4 integrin mAb after transfer to the membrane. Data shown are 
representative of three independent experiments. Cell line Raji served as a positive, Hone1 as 
a negative control. (B) Akata31 and (C) BJAB cells were incubated with mAb against integrin 
α4, α5, α6 αL, αV, β1, β2 and β7 and subsequently analysed by flow cytometry. (D) Akata31 
and BJAB (E) were incubated with antibodies against CD21 and HLA-DR and subsequently 
analysed by flow cytometry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Manuscripts 
 
 
84 
Figure 8 
 
 
 
Figure 8. Expression of α4 integrin in Akata31 cells correlates with higher susceptibility 
to infection with EBV. 
Akata31 (Fig. 8A and C) and BJAB (Fig. 8B and D) cells were incubated with the GFP EBV 
and after 72 hours, cells were analysed by flow cytometry for GFP. Graphs represent the 
results from A and B in numbers. Results are expressed as the mean percentage of infected 
cells or the MFI. The results derive from three independent experiments. 
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Supplementary 1 
 
 
 
Figure S1. Comparison by quantitative real-time PCR of integrin mRNA expression in 
TBCs, Raji, BJAB, Akata31, Akata Takada, BL2, L2 and Mutu I cells. 
Expression level of selected integrins was determined using real-time PCR. mRNA 
expression is shown of eight α  and three β subunits. The real-time PCR data was expressed as 
mRNA levels relative to hydroxymethylbilane synthase (HMBS).  
Values are depicted as 2-Δct. 
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Lentiviral Transduction Particles:  
 
 
Lentiviral transduction particles from Sigma Aldrich 
 
 
Particles Order number Sequences Name TU/ml  
Control  particles SHC002V MISSION  Non-target shRNA 2.6x107 
 SHC003V MISSION  TurboGFP control particles  2.7x107 
 SHC008V MISSION  B2M (beta 2 microtubulin) 3.2x107 
SHCLNV-NM_00085  TRCN0000029654 S1 α4 3.7x106 
 TRCN0000029655 S2  4.5x106 
 TRCN0000029656 S3  5.4x106 
 TRCN0000029657 S4  5.6x106 
 TRCN0000029658 S5  9.9x106 
SHCLNV-NM_001006658 TRCN0000057113 S1 CD21  8.9x106 
 TRCN0000057114 S2  2.6x106 
 TRCN0000057115 S3  6.5x106 
 TRCN0000057116 S4  3.3x106 
 TRCN0000057117 S5  4.1x106 
 
